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ABSTRACT 
 Ischemic stroke is a leading cause of morbidity and mortality in the world, 
and inflammation can have a significant impact on stroke severity.  Sustained 
inflammation after stroke can have detrimental effects; however, certain 
inflammatory cell types and mediators can also produce beneficial effects.  
Mineralocorticoid Receptor (MR) antagonists are used clinically to treat heart 
failure and also have beneficial effects in preclinical models of stroke 
independent of blood pressure lowering.  MR has been shown to regulate 
macrophage activation and polarization, and MR antagonists can induce an anti-
inflammatory, alternative macrophage phenotype.  In this dissertation, we show 
that genetic ablation of MR in myeloid cells is neuroprotective during ischemic 
stroke. We demonstrate that myeloid MR inactivation significantly reduces infarct 
volume and suppresses the pro-inflammatory response to stroke.  This 
delineates a previously unknown mechanism of pharmacological control by MR 
antagonists during stroke.  Neuroprotection by myeloid MR knockout occurs 
within two hours after reperfusion and was detected in a transient ischemia-
reperfusion model, but not during permanent occlusion.  In contrast to previously 
defined sexual dimorphic effects of MR antagonists during stroke, myeloid MR 
knockout ameliorates cerebral ischemia-reperfusion in both males and females.  
These data define a novel role for myeloid MR during stroke, and demonstrate 
the importance of MR-regulated myeloid cell phenotypes during the inflammatory 
response to stroke. 
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CHAPTER 1 
Introduction 
 
Stroke burden and current interventions 
 Stroke is the second leading cause of death worldwide and represents one 
of the major causes of long-term disability. On a global scale represented by a 
large percentage of low and middle-income countries, the incidence of stroke 
continues to rise.1 In the US and other high-income countries, stroke incidence 
and mortality are decreasing,1, 2 but this is associated with an increase in the 
number of years lived with disability.3 The majority of patients that survive a 
stroke suffer from various physical and cognitive neurological deficits, and the 
physical and psychological burden can be devastating for patients and their 
families. Stroke also represents a major financial burden not only on patients, but 
also on healthcare systems. In the US, the cost of stroke in 2010 was estimated 
to be 36.5 billion dollars, and these values are projected to triple within the next 
twenty years.2  
 Reduction in modifiable risk factors like hypertension, atrial fibrillation, 
hypercholesterolemia, smoking, diabetes, and physical inactivity can greatly 
reduce the incidence of stroke, and a wide range of pharmacotherapies are 
available to aid in the reduction of these risk factors. In contrast, very few 
therapeutic interventions are available to treat stroke after it has occurred. 
Thrombolytic therapy with tissue plasminogen activator (tPA) is the only 
efficacious pharmacological agent used clinically to treat ischemic stroke, but its 
use is limited by the time frame in which it must be administered. Endovascular 
thrombectomy using a mechanical clot retrieval device is another approved 
therapeutic intervention and is an alternative for patients that cannot receive
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thrombolytic therapy. However, recent clinical trials indicate that endovascular 
therapy by thrombectomy or endovascular tPA provides no additional benefit 
compared to intravenous thrombolytic therapy, and therefore in most cases 
endovascular therapy is seemingly less favorable due to the invasiveness, cost 
and increased time to recanalization.4-6  
 Although thrombolytic therapy has provided significant benefit in reducing 
ischemic stroke mortality and disability, there are major limitations for its use. 
Time until recanalization is critical, not only because prolonged ischemia 
increases neuronal death, but also because delayed administration of tPA 
increases the risk for hemorrhagic transformation and results in a poor outcome. 
Because of these problems, current guidelines recommend the administration of 
tPA within 4.5 hours of onset of stroke symptoms.7 Therefore, delayed diagnosis 
may preclude many patients from receiving thrombolytic therapy, and the most 
recent data indicate that from 2010-2011, only 7% of patients with ischemic 
stroke received thrombolytic therapy.8 This small percentage is largely due to the 
fact that only 25% of patients arrive to the emergency department within 3 hours 
of onset of stroke symptoms.9 An additional problem is that of the tPA-eligible 
patients who arrive within the recommended time window, only 77% received 
thrombolytic therapy, although this is a significant improvement since 2003 when 
only 43% of eligible patients received thrombolytic therapy.8 Several preclinical 
studies have identified ways to block tPA-induced blood-brain barrier breakdown 
and hemorrhagic transformation, which may extend the therapeutic window;10, 11 
however, no clinical trials have been completed to confirm a clinical benefit.  
 Since a large percentage of patients are ineligible for tPA, there is a critical 
need to develop new therapeutic agents for the treatment of stroke. After 
therapeutic thrombolysis or spontaneous recanalization, reestablishment of blood 
flow can restore oxygen and glucose supply to the brain, but it can also have 
detrimental effects by inducing reperfusion injury. Therefore, the development of 
novel neuroprotective agents may be useful even for patients receiving 
thrombolytic therapy. Stroke is a complex, multifaceted disease with many 
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pathophysiological processes contributing to neurological injury, and a thorough 
understanding of these processes is necessary to identify ideal therapeutic 
targets. Some of the major pathological mechanisms of stroke damage include 
energy deficit, excitotoxicity, ion dysregulation, oxidative stress, apoptosis, peri-
infarct depolarization and inflammation, and many pre-clinical therapeutic agents 
have been developed to target these pathogenic mechanisms of neurological 
damage.  
 This chapter will provide an overview of the mechanisms of inflammatory 
and immune-mediated damage during stroke. It will place particular emphasis on 
the role of immune cell recruitment, activation and regulation, while highlighting 
specific cell types and signaling targets with the potential for pharmacological 
therapy. It will further describe the connection between mineralocorticoid receptor 
activation and immune cell function, which is the basis for the hypothesis and 
focus of this dissertation. 
Inflammatory signaling in the brain 
 Neurons are extremely sensitive to changes in oxygen and glucose. 
During ischemia they rapidly communicate with other cells of the neurovascular 
unit by secreting cytokines, chemokines, nucleotides, and damage-associated 
molecular patterns (DAMPs).12 These signals activate glia and vascular cells to 
induce a series of neuroprotective responses that can provide metabolic support 
and attempt to increase perfusion to ischemic tissue. However, often the 
ischemic insult is too overwhelming for local neuroprotective mechanisms to 
compensate and a massive inflammatory response ensues. Inflammatory 
signaling pathways are stimulated immediately after ischemia occurs, and these 
responses have both beneficial and harmful effects depending on the specific 
cytokines and the specific phases of the ischemic response.  
 Increased inflammatory cytokines are detected in cerebrospinal fluid and 
serum of patients within 24 hours of acute stroke, and serum concentrations of 
inflammatory cytokines have been found to correlate with disease severity and 
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may be predictive of stroke outcome.13-15 The presence of high concentrations of 
proinflammatory cytokines IL-6 and TNF-α are associated with stroke 
worsening,16 whereas patients with higher concentrations of the anti-
inflammatory cytokine IL-10 have improved stroke outcomes.17 Similarly, 
inflammatory cytokines are also highly upregulated in animal models of cerebral 
ischemia and have been shown to have critical roles in stroke pathophysiology. 
 Inflammatory responses are not inherently bad and are initiated as a 
neuroprotective response to ischemia. However, after prolonged ischemia where 
cerebral blood flow is not restored, the milieu of inflammatory cytokines promotes 
a wide array of effects including apoptosis, reactive oxygen species generation, 
leukocyte recruitment and activation, complement activation, coagulation and 
changes in fibrinolysis that result in exacerbation of stroke damage (Figure 1.1).12 
Inflammatory cytokines contribute to rapid deterioration of the blood-brain barrier 
through both direct and indirect mechanisms. They can stimulate the production 
of reactive oxygen species and matrix metalloproteinases in numerous cells, 
which induce break down of the blood-brain barrier and facilitate the infiltration of 
circulating leukocytes.18, 19 
 Because of the numerous cell types involved and the complexity of cellular 
interactions during stroke, fully defining the roles for specific cytokines is difficult. 
Through the use of genetic and molecular techniques, both pathological and 
protective roles for many of the major inflammatory and anti-inflammatory 
cytokines have been defined (Table 1.1). While many proinflammatory cytokines 
like IL-1β, IL-12, and IL-17 seem to have predominantly harmful roles during 
stroke, others like TNF-α appear to have more complex functions and have been 
shown to produce both beneficial and detrimental effects.20, 21 Compared to other 
proinflammatory cytokines, IL-6 appears to be largely protective during stroke. 
Several anti-inflammatory cytokines like IL-10, TGF-β and IL-4 have also been 
found to have protective roles during stroke. Importantly, many preclinical studies 
have shown that targeting inflammatory signaling can affect stroke outcome, and  
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Figure 1.1. Immune cell interactions and mechanisms of damage during 
stroke. Dying neurons secrete DAMPs, which elicit rapid activation of resident 
microglia and macrophages. Resident microglia and recruited immune cells 
secrete inflammatory cytokines and generate reactive oxygen species (ROS), 
which promote leukocyte recruitment, blood-brain barrier (BBB) breakdown, and 
exacerbate neuronal damage. 
 
inhibition of detrimental cytokines or administration of protective cytokines can 
protect against stroke (Table 1.1).  
 As ischemic neurons begin to die, they release various intracellular 
molecules like DAMPs that signal other cells and initiate inflammatory responses. 
These signals contribute to the activation of classical proinflammatory signaling 
responses during stroke through the activation of toll-like receptors (TLRs). Upon 
activation by DAMPs, TLRs can induce the expression of inflammatory cytokines  
and can regulate cellular inflammatory responses. HMGB1 is one of the  
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Table 1.1 Role of cytokines in ischemic stroke models. 
 
 
well-studied DAMPs, and has been shown to promote stroke damage. 
Administration of recombinant HMGB1 protein exacerbates stroke,53-55 where as 
treatment with anti-HMGB1 neutralizing antibodies is protective during 
experimental stroke.53, 56 Similarly, interruption of TLR2 54, 57-60 and TLR4 54, 61, 62 
signaling is also protective in animal models of stroke.  
 While the literature demonstrates that inflammatory cytokines and 
signaling molecules have important roles in stroke, there is still much to be 
known. Many resident cells and recruited immune cells secrete and respond to 
numerous cytokines, and the major cell sources of the cytokines and the 
Detrimental Roles    
Cytokine Treatment   Phenotype Ref 
IL-1 IL-1β infusion Exacerbation 22 
 IL-1β KO No effect 23 
 IL-1α KO No effect 23 
 IL-1α/β KO Neuroprotection 23 
 ICE KO Neuroprotection 24 
    
IL-12 Neutralizing Ab Neuroprotection 25 
    
IL-17 KO Neuroprotection 26 
    
IL-23 KO Neuroprotection 26 
 Neutralizing Ab Neuroprotection 25 
    
TNF-α  TNF-α infusion Neuroprotection 27 
 TNF-α infusion Exacerbation 28 
 TNF-α KO Exacerbation 29 
 TNF-α inhibition Neuroprotective 28, 30-32 
 TNFR KO Exacerbation 33, 34 
    
Protective Roles    
Cytokine Treatment Phenotype Ref 
IL-1RA rhIL-1RA  Neuroprotection 35-37 
 IL-1RA KO Exacerbation 38 
    
IL-10 IL-10 (rIL-10, viral delivery, TG,) Neuroprotection 39-41 
 KO Exacerbation 42 
    
TGF-β  TGF-β infusion / viral delivery Neuroprotection 43, 44 
 TGF-βRIIs-Fc (decoy receptor) Exacerbation 45 
    
IL-4 KO Exacerbation 46 
    
IL-6  IL-6 infusion Neuroprotection 47-49 
 IL-6R Neutralizing Ab Exacerbation 50 
 KO Exacerbation / No Effect 51, 52 
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important target cells of the cytokines have not been fully defined in vivo. The 
complexity is further increased by the temporal changes that occur during injury, 
leading to an incomplete understanding of these cytokines during disease. In 
addition, immune cells are major secretors of inflammatory cytokines during 
stroke, and a large body of work has identified critical roles for specific immune 
cell types during stroke.  
Resident and blood-borne immune cells in the uninjured brain 
 The brain is comprised of numerous cell types and each has important 
roles in maintaining normal brain function. It is estimated that neurons account for 
50% of all of the cells in the human brain, while glia and vascular cells comprise 
the remaining half.63 Astrocytes, oligodendrocytes, and microglia comprise the 
majority of glial cells, and endothelial cells, smooth muscle cells and pericytes 
are associated with the vasculature. In normal physiology, glia have essential 
functions like clearance of neurotransmitters, providing metabolic support, 
myelination, phagocytosis, antigen presentation, and repair. Although the specific 
functional roles of each of these cells are unique, they all serve the common 
purpose of supporting neuron function.  
 Although lymphocytes, macrophages, and dendritic cells are present in the 
healthy brain, they are restricted to specific locations and are generally not found 
in the brain parenchyma because of the highly regulated brain environment.64 
Collectively, neuron and non-neuronal cells are often referred to as the 
neurovascular unit, because they are in close proximity, they exhibit highly 
dynamic interactions, and they work cooperatively to tightly regulate brain 
environment and function. One of the functions of the neurovascular unit is to 
maintain blood-brain barrier integrity, and this serves to protect the brain from 
dangerous substances, but also prevents cells from entering the brain. In fact, 
the central nervous system is one of the most privileged tissues in the body 
because peripheral immune cells have very limited access to the brain 
parenchyma. Compared to other tissues, the brain vasculature has significantly 
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decreased expression of adhesion molecules P-selectin and E-selectin even in 
the presence of inflammatory cytokine stimulation,65 and this significantly inhibits 
TNF-α-induced leukocyte rolling in the brain.  
 Resident microglia serve as the major sentinel immune cells in the brain. 
Microglia are tissue-resident macrophages that carryout functions including 
tissue surveillance, phagocytosis of dying neurons, and antigen presentation. 
The origin and replacement of senescent microglia has been controversial until 
more recently. While it was once thought that tissue-macrophages, including 
microglia, were maintained by monocytes precursors, it is now thought that they 
are replenished almost exclusively by local proliferation. In fact, several studies 
have confirmed that microglia are established prenatally from yolk sac 
progenitors and are maintained throughout adulthood through local 
proliferation.66-69 Bone marrow-derived cells engraft in the CNS and give rise to 
microglia under specific conditions like brain irradiation and bone marrow 
transplantation.70-73 However, brain shielding and parabiosis studies have shown 
that even during injury, local proliferation is responsible for maintenance of 
microglia populations.74-77 During injury, microglia rapidly expand by in situ 
proliferation and undergo microgliosis, and one study found that increased 
microglia proliferation was actually associated with decreased injury.78  
Recruitment of blood-borne leukocytes after stroke 
 In the uninjured brain, access by immune cells is largely restricted. After 
ischemic injury, reactive oxygen species, proteases and inflammatory signaling 
leads to blood-brain barrier breakdown, and inflammatory cytokines further 
upregulate adhesion molecules and promote the transmigration of leukocytes into 
the brain parenchyma. The kinetics of leukocyte trafficking has been 
characterized in animal models of stroke. Not surprisingly, studies have found 
that microglia are the first immune cells to respond and undergo rapid activation 
and proliferation in ischemic tissue.79 Macrophages, neutrophils, and dendritic 
cells also respond quickly and are present in greatest numbers between one to 
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three days after ischemia. Although many studies have shown that the number of 
blood-borne neutrophils and macrophages are greatest after twenty-four hours, 
they are likely present much earlier, albeit in smaller numbers. In a model of brain 
compression injury, inflammatory responses by macrophages and neutrophils 
were shown to occur within thirty minutes using a novel intravital two-photon 
laser scanning microscopy technique.80 During stroke, the number of early 
responding leukocytes may be relatively small compared to later time points, but 
they may still have an important role in regulating inflammation during stroke.  
 Since immune cells are major secretors of inflammatory cytokines and 
contribute to stroke damage, general strategies to inhibit immune cell recruitment 
are promising and have been effectively employed in experimental models of 
stroke. Secreted chemokines promote the recruitment of leukocytes to ischemic 
tissues, and several major chemokines, MCP1, RANTES, and CX3CL1 are 
upregulated during stroke. Genetic deficiency of these chemokines or their 
receptors reduces immune cell recruitment during stroke and is neuroprotective, 
suggesting a detrimental role for leukocyte recruitment during stroke (Table 1.2). 
As mentioned above, inflammatory cytokines also promote leukocyte adhesion, 
activation and transmigration into the parenchyma through upregulation of 
adhesion molecules. Strategies to block leukocyte transmigration through genetic 
deletion or inhibition of P-Selectin, E-Selectin, CD11b, and ICAM-1 have also 
been found to be neuroprotective and reduce leukocyte numbers in the brain 
after stroke (Table 1.2).  
 Immune cells recruited to the ischemic brain can originate from several 
sources (Figure 1.2). Initially neutrophils, monocytes, dendritic cells and 
lymphocytes are recruited directly from the circulation, although after sustained 
inflammation they are also mobilized from the bone marrow. Monocytes are 
largely produced in the bone marrow from hematopoietic precursors in the 
steady-state and are recruited to the circulation during stroke via CCR2. Although 
the bone marrow is known to be the major source of monocytes, more recently 
the spleen has been identified as a reservoir for monocytes,81 and can  
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Table 1.2 Inhibition of immune cells in ischemic stroke models. 
        
        Mp – macrophages, Mo – monocytes, Pc – phagocytic cells 
give rise to monocytes through extramedullary monocytopoiesis during 
disease.112, 113 Spleen-derived cells likely contribute to immune cell-mediated  
stroke damage, and a reduction in spleen size has been documented in both 
humans and animal models.114, 115 Moreover, splenectomy has been shown to be 
protective and reduces immune cell-mediated damage in several models of 
organ damage,116, 117 including brain injury,118 and stroke.119-121  
Inhibition of leukocyte recruitment    
Target Treatment Phenotype Ref 
Mac-1 (CD11b/CD18) Neutralizing Ab Neuroprotection 82-84 
 KO Neuroprotection 85 
    
P-Selectin Neutralizing Ab Neuroprotection 86, 87 
 KO Neuroprotection 88 
    
E-Selectin Neutralizing Ab Neuroprotection 89 
    
ICAM-1 Neutralizing Ab Neuroprotection 82, 90-92 
 KO Neuroprotection 93 
    
MCP1 KO / Knockdown Neuroprotection 94-96 
 TG-overexpression Exacerbation 97 
    
CCR2 KO Neuroprotection / No Effect 98, 99 
    
CX3CL1 KO Neuroprotection 100 
    
CX3CR1 KO Neuroprotection 101 
    
    
Cell Depletion or Enhancement    
Target Treatment Phenotype Ref 
Mp/Mo/Pc Clodronate liposomes Exacerbation 102, 103 
 CD11b-DTR Exacerbation 103 
    
T cells Rag1 -/- Neuroprotection 104, 105 
 Rag2 -/- Neuroprotection 26 
 SCID Neuroprotection 106 
    
Tregs FoxP3DTR No effect 107 
 DEREG Neuroprotection 108 
 Anti-CD25 Ab Exacerbation 109 
 Adoptive transfer Neuroprotection 110 
    
B cells µMT -/- Exacerbation 111 
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Figure 1.2. Origin and recruitment of blood-borne cells to the ischemic 
brain. During stroke, chemokines mobilize immune cells to the circulation from 
various sources including the bone marrow, spleen and other lymphatic tissues.  
 
 While these strategies have provided evidence that non-selective inhibition 
of leukocyte recruitment can block inflammation-mediated stroke damage, more 
recent studies have begun to define the role of specific immune cell types. 
Lymphocytes are present in the ischemic brain and are known to have important 
roles in adaptive immune responses. Most data suggest that T-cells have a 
detrimental role since mice deficient in T-cells are protected in models of stroke 
(Table 1.2). Although lymphocytes can develop autoimmune responses against 
brain antigens, they appear to contribute to stroke damage through other 
mechanisms, perhaps through controlling innate immune cell responses. 
Adaptive immune responses typically require several days to develop, where as 
studies have found that T-cell depletion is protective during earlier time points. 
Regulatory T-cells (Tregs) have been the focus of more recent studies, although 
there is controversy regarding whether this subset of T-cells has a beneficial or 
detrimental role. Several studies in which Tregs were depleted prior to stroke 
have found opposite effects, where as adoptive transfer has been shown to 
decrease stroke damage (Table 1.2). These data indicate that T-cell responses 
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predominantly exacerbate stroke, although specific subsets may be beneficial 
and could be potential therapeutic targets.  
 Ablation of CD11b+ cells using a transgenically expressed diphtheria toxin 
receptor (DTR) has no effect on infarct size during stroke, but increases 
hemorrhagic transformation and impairs neurological function.103 Similarly, 
another study found that intracerebroventricular injection with clodronate 
liposomes, which ablates phagocytic cells, enhanced proinflammatory cytokines 
after stroke, and impaired neurological function.102 Depletion of microglia in the 
developing brain is also detrimental to neuron function and results in increased 
apoptosis.122 These results suggest that while prolonged microglia and 
macrophage activation may exacerbate stroke, depletion of these cells is also 
detrimental and probably interferes with critical phagocytic and reparative 
function. Moreover, perturbing the function of one cell type affects the function of 
many others that work cooperatively in the neurovascular unit. 
 Modulating specific immune cell phenotypes to ameliorate disease is an 
enticing strategy and could be an important therapeutic approach. In contrast to 
depleting or blocking macrophage responses, manipulation of the macrophage 
phenotype may provide a novel way to prevent specific deleterious inflammatory 
effects, while still allowing for other critical phagocytic and reparative responses. 
However, very few studies have focused on modulating myeloid phenotypes 
during stroke.  
Macrophage phenotypes during disease 
 Macrophages exhibit a wide array of functionally diverse phenotypes in 
response to pathogens or tissue injury. Through the integration of environmental 
signals, macrophages respond with unique activation programs, which carryout 
specific functional roles. Initially, macrophages were classified as classically 
activated macrophages (CAMs) and alternatively activated macrophages 
(AAMs), and were defined as M1 and M2, based on induction by Th1 and Th2 
cytokines. Other classification schemes based on in vitro stimuli have also been 
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proposed, but have not gained wide acceptance likely because the in vivo 
phenotypes do not correspond well. These definitions are insufficient since the 
chemical milieu in vivo is much more complex and the macrophage phenotypes 
are context dependent. Others have taken the approach to name macrophages 
based on the expression of a particular marker (e.g. Mox, a type of alternatively 
activated macrophage expressing heme oxygenase). However, the functions of 
the different phenotypes are poorly understood and the markers used to identify 
them often do not have clear functional significance in the phenotype. It is now 
generally accepted that macrophage phenotypes fall within a spectrum of 
functional phenotypes, although they can have similar and overlapping features 
as the CAM and AAM phenotypes induced by Th1 and Th2 cytokines in vitro 
(Figure 1.3).  
 
 
 
Figure 1.3. Spectrum of classically and alternatively activated macrophage 
phenotypes. A.) Classical activation is regulated in vivo in response to an array 
of inflammatory stimuli such as IFN-γ, TLR activation and inflammatory cytokines, 
and results in the expression of proinflammatory mediators like TNF-α, IL-1β, IL-6 
and a respiratory burst generating ROS. B) Phenotypes in the spectrum of 
alternative activation have unique gene expression profiles, and there is 
significant overlap in the previously defined wound healing, HO-1+ and 
deactivation subsets. 
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 CAMs are generally proinflammatory and are induced through stimulation 
with IFN-γ or by activation of pattern recognition receptors. CAMs are present in 
type 1 immune responses and promote inflammation by secreting classic pro-
inflammatory cytokines like TNF-α, IL-1β, IL-6, and IL-12, and by the production 
of reactive oxygen species through upregulation of oxidative mediators like iNOS 
and NADPH oxidase. In contrast, AAMs induced by IL-4/IL-13 have a different 
transcriptional profile with increased expression of Arg1, Ym1, IL-10, mannose 
receptor (CD206) and others.123-125 Heme oxygenase-1 (HO-1) has emerged as 
an additional marker for a macrophage phenotype that falls within the spectrum 
of alternative activation (Figure 1.3). AAMs are involved in parasitic infection and 
are also involved in wound healing response and resolution of inflammation. In 
many cardiovascular diseases, AAMs are present and are thought to have 
protective roles. The presence of AAM phenotypes has been associated with 
cardioprotection, although little is known about the functional significance of AAM 
markers, and the protective mechanisms of these macrophage phenotypes are 
largely unknown.  
 Over half of the nuclear receptor superfamily is expressed in 
macrophages, and many nuclear receptors have important roles in regulating 
macrophage activation and function.126 Many of the nuclear receptors orchestrate 
the macrophage inflammatory response through regulation of inflammatory 
pathways and by regulating the expression of inflammatory mediators. The 
glucocorticoid receptor (GR) is one of the most extensively studied nuclear 
receptors in regards to inflammation and macrophage function, and 
pharmacological modulation of GR can suppress inflammatory pathways and 
alter the macrophage phenotype.127 GR activation by glucocorticoids increases 
the production of anti-inflammatory cytokines, IL-10 and TGF-β and down-
regulates MHC-II resulting in macrophage deactivation, sometimes referred to as 
regulatory macrophages. Other nuclear receptors like PPAR-γ, LXR, and MR 
have also more recently been shown to regulate macrophage polarization.  
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 The role of AAM phenotypes during stroke is unclear, although recent data 
suggest that enhanced alternative activation may be beneficial.128 AAM markers 
are increased and persist for several days after transient ischemic stroke, and 
one study found AAM markers are localized within the ischemic core.129, 130 IL-4 
knockout mice have altered inflammatory responses to a variety of stimuli and 
have diminished Th2 responses and reduced alternative activation. Xiong et al. 
reported that IL-4 knockout mice have exacerbated cerebral infarction and 
impaired neurological function.46 Importantly, IL-4 knockout mice have increased 
macrophage and microglia recruitment and an increase in the Th1/Th2 ratio. This 
supports a hypothesis for a protective role of alternatively activated macrophages 
during stroke. In addition, microglia also adopt classical and alternatively 
activated phenotypes,131-133 although little is known about their role in vivo and 
whether microglia phenotypes can be altered to produce neurological benefit. 
Mineralocorticoid receptor biology and cardiovascular disease 
 The mineralocorticoid receptor (MR) is a nuclear receptor with expression 
in a wide range of tissues, although it is most well known for its classical role in 
the renin-angiotensin-aldosterone-system. In the distal nephron, MR is largely 
responsible for regulating sodium reabsorption, which has important roles in 
controlling extracellular blood volume and blood pressure (Figure 1.4). 
Aldosterone is the physiological ligand for MR in the kidney, but MR actually has 
two high affinity ligands: aldosterone and corticosterone. Under normal 
physiological conditions, cortisol is present at concentrations that are 100- to 
1000-fold greater than aldosterone,134 and with an equal affinity as aldosterone, 
cortisol would normally occupy MR . However, sensitivity to aldosterone can be 
achieved by the presence of 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), 
which converts cortisol into a low-affinity form, cortisone. Therefore tissues with 
high 11β-HSD2 expression are sensitive to aldosterone, but not cortisol.  
 Because of their diuretic and antihypertensive effects, the MR antagonists 
spironolactone and eplerenone have been used clinically for the treatment of  
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Figure 1.4. Classical role of the mineralocorticoid receptor in the kidney. 
Activation of the RAAS leads to the secretion of aldosterone from the adrenal 
cortex, which travels to target cells in the kidney and activates MR. 11β-HSD2 
converts cortisol into the low affinity form cortisone, thus allowing aldosterone to 
activate MR and increase sodium reabsorption in the distal nephron.  
 
hypertension, edema, and hyperaldosteronism. More recently, the beneficial 
effects of MR antagonists have been found to extend beyond diuresis and blood 
pressure lowering. In patients with severe heart failure, clinical trials have found 
that MR antagonism significantly decreases mortality independent of blood 
pressure lowering.135, 136 These studies indicate that MR has more direct effects 
in regulating pathological hypertrophy and remodeling. Subsequent studies have 
focused on identifying novel roles for MR in different cell types including 
cardiomyocytes, smooth muscle cells, endothelial cells, and macrophages, and 
many have identified pathological roles in models of hypertensive remodeling and 
myocardial infarction.137-143  
 We have recently identified MR as a regulator of macrophage polarization. 
Activation of macrophages by mineralocorticoids enhances proinflammatory CAM 
phenotypes, whereas MR antagonists and MR knockout suppress the 
inflammatory response and skew macrophages towards an AAM phenotype 
(Figure 1.5). Myeloid-specific deletion of MR significantly reduced cardiac 
hypertrophy and fibrosis in a hypertensive and inflammatory model of cardiac 
remodeling. Myeloid MR knockout also resulted in the suppression of  
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Figure 1.5. Regulation of macrophage phenotype by the mineralocorticoid 
receptor. MR activation in macrophages induces a CAM phenotype and 
enhances LPS-induced CAM polarization. MR knockout or MR antagonism 
suppresses classical activation and induces an AAM phenotype. 
 
inflammatory genes and increased the expression of AAM markers in cardiac 
tissue. These data indicate that modulation of myeloid cell phenotype is an 
important mechanism for the beneficial effects of MR antagonists used clinically 
to treat pathological cardiac remodeling. 
 Several preclinical studies have shown that MR antagonists also provide 
significant benefit during animal models of ischemic stroke.144-146 In stroke-prone 
spontaneously hypertensive rats, spironolactone decreases stroke related 
mortality and also reduces ischemic infarct volume after middle cerebral artery 
(MCA) occlusion.144, 147 Similarly, spironolactone and eplerenone reduce infarct 
volume and decrease superoxide production in both permanent and transient 
MCA occlusion.  
 In this thesis, we examine the role of myeloid MR during stroke. Based on 
the efficacy of MR antagonists in preclinical stroke models, and our previous data 
Arg1
Ym1
CD206
Fizz1
Mgl
AAM
,/ȕ
TNFĮ
IL-12
MCP1
CCL5
MR
CAM
MR knockoutMR
 Ac
tiva
tion MR antagonist
Monocyte / Unactivated Macrophage
LP
S
MREplerenone
Spironolactone
ALDO
Cardiovascular ProtectionCardiovascular Damage
	   18 
showing that MR regulates the macrophage phenotype, we hypothesized that 
MR controls myeloid cell phenotype during stroke pathophysiology. 
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CHAPTER 2 
Myeloid-Specific Deletion of the Mineralocorticoid Receptor Reduces 
Infarct Volume and Alters Inflammation During Focal Cerebral Ischemia 
 
Abstract 
Background and Purpose – Mineralocorticoid receptor (MR) antagonists have 
protective effects in rodent models of ischemic stroke, but the cell type-specific 
actions of these drugs are unknown. In the present study, we examined the 
contribution of myeloid cell MR during focal cerebral ischemia using myeloid-
specific MR knockout (MyMRKO) mice. 
Methods – MyMRKO mice were subjected to transient (90 minute) middle 
cerebral artery occlusion (MCA) occlusion followed by 24 hours reperfusion (n = 
5-7/group). Ischemic cerebral infarcts were identified by hematoxylin and eosin 
staining and quantified with image analysis software. Immunohistochemical 
localization of microglia and macrophages was performed using Iba1 staining, 
and the expression of inflammatory markers was measured after 24 hours 
reperfusion by qRT-PCR.  
Results – MyMRKO resulted in a 65% reduction in infarct volume (P = 0.005) 
following MCA occlusion. This was accompanied by a significant reduction in 
activated microglia and macrophages in the ischemic core. Furthermore, 
MyMRKO suppressed classically activated M1 macrophage markers TNF-α, IL-
1β, MCP1, Mip1α and IL-6 while partially preserving the induction of alternatively 
activated, M2, markers Arg1 and Ym1.  
_______________________ 
This chapter represents a published article: Frieler, R.A., Meng, H., Duan, S.Z., 
et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct 
volume and alters inflammation during cerebral ischemia. Stroke. 2011;42:179-
185.
	  
	  
33 
Conclusions – These data demonstrate that myeloid MR activation exacerbates 
stroke and identify myeloid MR as a critical target for MR antagonists. Further, 
these data indicate that MR activation has an important role in controlling 
immune cell function during the inflammatory response to stroke. 
Introduction 
Mineralocorticoids can cause vascular inflammation and hypertension, 
which lead to vascular damage and remodeling.1 During ischemic stroke, 
mineralocorticoid receptor (MR) activation results in increased vascular damage 
and ischemia.2 Not surprisingly, several studies have shown that MR antagonists, 
at doses that do not alter blood pressure, are protective in rodent models of 
ischemic stroke. Treatment with the MR antagonist spironolactone was shown to 
reduce vascular damage and decrease mortality.3 Similarly, another MR 
antagonist, eplerenone, decreases superoxide production and reduces infarct 
volume in animal models of ischemic stroke.4 This indicates that MR blockade 
might have clinical potential as a therapeutic agent for stroke. However, the 
mechanisms of pharmacologic control and, importantly, the cell type-specific 
actions of MR antagonists have not been identified and characterized.  
In addition to its classical role in the kidney, MR has also been identified in 
other tissues, including the heart, brain, and inflammatory cells such as 
macrophages and microglia.5, 6 In many of these cells, particularly brain and 
hematopoietic cells, the ligand for MR is thought to be glucocorticoids. MR has 
two high affinity physiologic ligands, mineralocorticoids such as aldosterone, and 
glucocorticoids such as corticosterone in rodents.7 Since glucocorticoids circulate 
at levels 100- to 1000-fold higher than mineralocorticoids, MR binding sites are 
thought to be occupied by glucocorticoids in the absence of 11β-hydroxysteroid 
dehydrogenase 2 (11β-HSD2) which inactivates corticosterone to 11β-
dehydrocorticosterone. Neurons and hematopoietic cells lack 11β-HSD2 and 
therefore the majority of MR molecules are predicted to be occupied by 
glucocorticoids.8 
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Inflammation has an important role in the pathogenesis of ischemic stroke. 
A reduction in immune cells, inflammatory cytokines, and adhesion molecules 
reduces stroke injury,9, 10 where as increases in anti-inflammatory cytokines such 
as IL-10 and IL-1RA are protective during models of cerebral ischemia.11, 12 
Several strategies to reduce the damaging inflammatory response following 
ischemic stroke have targeted immune cells and immune cell recruitment. 
Decreasing neutrophil infiltration reduces infarct volumes and neuronal cell death 
in mice following focal cerebral ischemia.10 However, there was no 
neuroprotection found in clinical trials that tested agents that reduced neutrophil 
activity.13 Similarly, adhesion molecules are important for leukocyte trafficking 
and infiltration into ischemic regions, and the use of monoclonal antibodies 
against intercellular adhesion molecule-1 (ICAM-1) has been successful in 
animal models of ischemic stroke.14, 15 Again, this treatment failed to translate to 
the clinical condition, but this was possibly due to the use of murine 
immunoglobulin. Targeting nuclear receptors that alter inflammation may be a 
viable alternative.  
We have recently identified MR as a regulator of macrophage polarization, 
and deletion of MR from macrophages induces an alternatively activated 
macrophage (AAM) phenotype, sometimes called M2, while suppressing the 
classically activated macrophage (CAM), M1, phenotype.16 Decreasing the 
CAM/AAM ratio was associated with abrogation of L-NAME/Angiotensin-II-
induced cardiac and vascular hypertrophy, fibrosis, and inflammation. Myeloid 
MR is also important in DOCA/salt-induced cardiac fibrosis.17 Importantly, our 
previous work showed these effects to be independent of blood pressure 
lowering and, rather, are proposed to be a result of MR control of macrophage 
activation. We therefore hypothesized that the neuroprotective effects of MR 
antagonists during cerebral ischemia are at least partially due to a modulation in 
myeloid cell response, particularly the CAM/AAM polarization of macrophages 
and microglia. To test this, we examined the effects of myeloid MR knockout 
(MyMRKO) in a model of focal cerebral ischemia. 
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Methods 
Mice 
 MyMRKO mice on a C57BL/6 background were bred by crossing 
homozygous floxed MR mice with homozygous floxed MR mice containing LysM-
Cre (MRfl/fl;LysM-Cre x MRfl/fl). MRfl/fl;LysM-Cre (knockouts) and littermate MRfl/fl 
(floxed controls (FC)) were used for all experiments. All animal procedures were 
performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (NIH Publication no. 80–23) and were approved by the University 
Committee on Use and Care of Animals of the University of Michigan. 
Middle Cerebral Artery (MCA) Occlusion 
 Male MyMRKO mice weighing between 25-32 g were used. MCA 
occlusion was performed using the intraluminal filament method as previously 
described.18 The mice were anesthetized with 1-3% isoflurane and a 6-0 silicon 
rubber-coated nylon monofilament (Docoll Corporation, CA) was inserted into the 
right internal carotid artery. The right MCA was occluded for 90 minutes at which 
point the monofilament was removed and mice were allowed to recover.  
Laser Doppler Flowmetry and Blood Gas 
 Cortical perfusion in the MCA territory was measured using laser Doppler 
flowmetry and was determined before and during occlusion of the MCA. For 
measurement of pH, PO2, and PCO2, a catheter was implanted into the femoral 
artery and arterial blood was collected during pre-ischemic and ischemic periods.  
Measurement of Infarct Volume 
 Following 24 hours of reperfusion, the mice were euthanized and 
transcardially perfused with heparinized saline (1 U/mL). The brains were 
removed and post-fixed in 4% paraformaldehyde for 1 week. The cerebrum was 
then cut into 1 mm thick serial coronal sections. 10 μm paraffin embedded 
sections were stained with hematoxylin and eosin and the cerebral infarct volume 
was quantified using NIH image analysis software (Image J ver 1.43). Infarct 
volume was corrected for brain edema. 
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Immunohistochemistry 
 Microglia and macrophage activation and localization were determined 
after 24 hours of reperfusion with the microglia/macrophage selective antibody 
ionized calcium-binding adapter protein 1 (Iba1) (Abcam) at a 1:300 dilution using 
standard staining protocols on paraffin embedded sections. Iba1+ cells were 
quantified and expressed as number of cells/field (40X objective). Two 40X fields 
were counted per anatomical region and averaged to obtain the number of Iba1+ 
microglia and macrophages. 
Quantitative real-time RT-PCR 
 mRNA expression was measured after 24 hours reperfusion. Total RNA 
was extracted from frozen whole cerebral hemispheres using TRIzol reagent and 
then purified with the RNeasy Mini Kit (Qiagen). Purified RNA (1µg) was reverse 
transcribed to cDNA using an Applied Biosystems kit. QRT-PCR was performed 
using a Bio-Rad iCycler. The relative mRNA expression was quantified using the 
comparative method and mRNA was normalized to β-actin. 
Microglia Isolation and Culture 
 10-12 wk old mice FC and MyMRKO mice were euthanized and 
transcardially perfused with heparinized saline (1U/mL). The cerebrum was 
homogenized in ice cold PBS in a Tenbroeck homogenizer and the homogenate 
was passed through a 50 μm strainer and resuspended in 70% isotonic Percoll. 
A 0/40/70% Percoll gradient was set up and centrifuged at 1200 x g for 45 
minutes at 20°C. The microglia fraction was then collected, resuspended in RPMI 
+ 10% FBS and plated at a density of 2 x 105 cells/mL/well. Cells were washed 
with PBS (+ calcium chloride, + magnesium chloride) after 2 hours to remove 
non-adherent cells and then incubated for 24 hours at 37°C, 5% CO2. 
Statistics 
 Data are presented as mean ± SEM. Comparison of mean values between 
groups was performed using an unpaired, Student’s t test or by a two-way 
ANOVA with a Bonferroni post-test as indicated. P < 0.05 was considered 
statistically significant.  
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Results 
MyMRKO 
There are no obvious phenotypic differences in MyMRKO mice compared to 
floxed controls. Since MR is classically known to regulate blood pressure and this 
can affect stroke, we determined if MyMRKO affected blood pressure. We 
observed no significant change in baseline systolic and diastolic blood pressure 
between freely moving, unanesthetized MyMRKO and floxed control groups as 
measured by arterial pressure transducers monitored by radiotelemetry (Figure 
2.1A and B). There is also no change in heart rate between the groups (Figure 
2.1C). This would indicate that differences in neurologic outcome between the 
floxed controls and MyMRKO are unlikely to be related to blood pressure.  
Figure 2.1. Effect of MyMRKO on blood pressure. Data represent the mean 
systolic pressure (A), diastolic pressure (B), and heart rate (C) of floxed control 
(FC) and MyMRKO mice during day and night cycles determined by implanted 
arterial pressure transducers. n = 4 per group. 
 
MyMRKO reduces infarct volume. 
We examined the effect of MyMRKO on ischemic lesion size during focal 
cerebral ischemia. MyMRKO resulted in a significant reduction in infarct size 24 
hours after 90 minute transient occlusion of the right MCA. The infarct volume 
was determined in H&E stained serial coronal sections using Image J software, 
and a significant decrease in ischemic infarct size was detected in MyMRKO 
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sections (Figure 2.2A) relative to floxed controls (Figure 2.2B). Quantification of 
infarct volumes in serial coronal sections shows a significant reduction in 
MyMRKO (Figure 2.2C). The total infarct size of the ischemic hemisphere in the 
MyMRKO group was 11%, which was significantly less (P=0.005) than floxed 
controls, which had a total infarct volume of 32% (Figure 2.2D). This represented 
a highly significant 65% reduction in ischemic infarct volume in the MyMRKO 
group.  
 
 
Figure 2.2. Quantification of infarct volume following transient cerebral 
ischemia. Infarct volumes were calculated from H&E stained serial coronal 
sections after MCA occlusion and 24 hours reperfusion using Image J software. 
Representative photographs of MyMRKO (A) and floxed controls (FC) (B) 
showing a reduced infarct size in the MyMRKO group. Quantification of infarct 
volume in serial coronal sections of FC and MyMRKO mice (C) and quantification 
of total ischemic infarct size in whole brain hemispheres (D) also showed a 
significant reduction in infarct size in the MyMRKO group. n = 5-7 per group. **P 
< 0.01, *** P < 0.001, Bonferroni post-test.  
 
No differences in pH, PO2, or PCO2 were detected before or during ischemia 
(Table 2.1). Cerebral blood flow in the MCA territory was reduced to less than 
50% baseline during ischemia, but no differences were detected in perfusion 
between floxed control and MyMRKO mice.  
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Table 2.1. Cerebral blood flow and arterial blood gas measurements. 
 
Values represent mean ± S.E. The ischemic cerebral blood flow (CBF) is 
represented as the percentage of the pre-ischemic, baseline CBF. There were no 
significant differences between FC and MyMRKO mice (N = 4 per group). FC = 
Floxed Control, MyMRKO = myeloid MR knockout. 
 
Recruitment of microglia/macrophages following MCA occlusion. 
Following MCA occlusion, there were no differences in the number of microglia in 
the non-ischemic, contralateral hemisphere between floxed control and MyMRKO 
groups (Figure 2.3A). There was a robust increase in Iba1+ cells in the ischemic, 
ipsilateral core when compared to the non-ischemic, contralateral hemisphere in 
floxed controls, indicating an increase in microglia and/or macrophage  
recruitment. However, this response was reduced in MyMRKO mice. 
Quantification of Iba1+ cells/field showed a statistically significant reduction 
(P=0.018) in microglia/macrophages in MyMRKO in the ischemic core (Figure 
2.3B). A regional comparison of Iba1+ cells show that significant differences in 
microglia/macrophages are largely confined to the subcortical basal ganglia 
(Table 2.2), which is within the ischemic core.  
  CBF (%)  pH  PO2, mm Hg  PCO2, mm Hg 
Pre-Ischemia         
FC  100  7.34 ± 0.04  19.3 ± 3.9  158.7 ± 17.4 
MyMRKO  100  7.36 ± 0.06  17.6 ± 2.5  149.0 ± 14.8 
Ischemia         
FC  46.1 ± 0.9  7.28 ± 0.06  20.8 ± 4.1  138.6 ± 17.0 
MyMRKO  46.6 ± 3.8  7.39 ± 0.05  20.9 ± 4.6  140.7 ± 12.3 
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Figure 2.3. Immunohistochemical analysis of microglia and macrophages 
following MCA occlusion. Representative photomicrographs of non-ischemic 
contralateral (Contra) and ischemic ipsilateral (Ipsi) regions from coronal sections 
containing the infarct core. There were no significant changes in Iba1 staining in 
the contralateral hemispheres of floxed controls (FC) (A) or MyMRKOs (B). There 
was a significant increase in Iba1+ microglia and/or macrophages in the 
ipsilateral ischemic hemisphere of floxed controls (C), however, this response 
was diminished in MyMRKO mice (D). Quantification of immunoreactive Iba1+ 
cells shows a statistically significant reduction of activated microglia and/or 
macrophages in the ischemic core of MyMRKO relative to floxed controls (E). n = 
5-7 per group. 
 
MyMRKO alters the inflammatory response to stroke. 
We have previously demonstrated that myeloid MR controls macrophage 
polarization and alters the inflammatory response during cardiac inflammation 
and fibrosis.16 To determine whether MyMRKO alters the inflammatory response 
to ischemic stroke, we measured the expression of classical and alternative 
macrophage markers 24 hours after MCA occlusion using qRT-PCR. There is a 
strong induction in pro-inflammatory cytokines in the ischemic hemisphere of the 
floxed control group. However, MyMRKO demonstrated profound suppression of 
CAM markers TNF-α, IL-1β, MCP1 and Mip1α (Figure 2.4A). These pro-
inflammatory mediators are generally associated with exacerbation of tissue 
damage.  
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Table 2.2. Anatomical localization of Iba1+ cells following MCA occlusion.  
Anatomical Region  
 
Iba1+ cells / field   
FC   MyMRKO   
Mean ± 
S.E.  
 Mean ± 
S.E.  
P-value  
Basal ganglia      
Medial  123 ± 5   44 ± 8  < 0.001  
Lateral  101 ± 11   54 ± 11  0.011  
Cortex      
Primary Motor  19 ± 2   21 ± 1  0.329  
Secondary Motor  20 ± 1   21 ± 1  0.100  
Primary 
somatosensory  29 ± 2   22 ± 3  0.088  
Secondary 
somatosensory  31 ± 8   27 ± 2  0.280  
Olfactory area  32 ± 11   28 ± 2  0.332  
Hypothalamic area  31 ± 15   25 ± 4  0.337  
 
Values represent mean ± S.E. of Iba1+ cells observed in different anatomical 
regions within the cerebrum. Cells were counted in a 40X field. N = 5-7 per 
group. 
 
In contrast, the induction of AAM markers was at least partially preserved 
in MyMRKO. There was a significant increase in AAM markers, Arg1 and Ym1, in 
the ischemic hemisphere of both floxed control and MyMRKO groups (Figure 
2.4B); interestingly, no significant differences in these AAM markers in the 
ischemic hemisphere were observed between the MyMRKO and floxed controls. 
In MyMRKO, there was a minimal suppression of Arg1 and Ym1 (less than 2-
fold) where as all of the CAM markers were suppressed by greater than 2-fold 
and IL-1β and MCP1 had a 5-fold suppression relative to controls. Other AAM 
markers such as the mannose receptor (Mrc1) and Mgl1 showed no significant 
changes whereas the IL-1 receptor antagonist (IL-1RA) was significantly lower in  
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Figure 2.4. MyMRKO shows an altered inflammatory response during MCA 
occlusion. mRNA expression of CAM markers (A) AAM markers (B) and IL-17 
(C) following MCA occlusion. All genes were normalized to β-actin. n = 4 per 
group. 
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the MyMRKO group (Figure 2.4B). Aldosterone has been shown to induce IL-17- 
mediated neuroinflammation,19 but we did not see any significant change in the 
expression of IL-17 (Figure 2.4C). 
 Since oxidative stress is a critical mediator of reperfusion injury, we 
determined if MyMRKO altered the expression of genes associated with oxidative 
stress. We found no significant stroke-induced or strain-dependent differences in 
several genes (NADPH oxidase 2 (NOX2), manganese superoxide dismutase 
(MnSOD), catalase (Cat), and peroxiredoxin-2 (Prdx2)) (Figure 2.5) that are 
known to contribute to oxidative damage and that are associated with 
inflammation.  
Figure 2.5. Markers of oxidative stress and fibrosis. MyMRKO did not show 
any differences in the mRNA expression of markers of oxidative stress NADPH 
oxidase 2 (NOX2), manganese superoxide dismutase (MnSOD), catalase-1 
(Cat), peroxiredoxin-2 (Prdx2), nor did it show a difference in the expression of 
collagen 1A (Col1A1), collagen 3 (Col3) or Fibronectin (Fn). No difference was 
observed in the expression of matrix metalloproteinase 9 (MMP9). All genes were 
normalized to β-actin. FC = Floxed Control, n = 4 per group. 
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In cardiac inflammation and fibrosis, myeloid MR was shown to 
exacerbate tissue remodeling and increase fibrosis. However, no changes in 
collagen 1A (Col1A1), collagen 3 (Col3), and fibronectin (Fn) expression were 
detected, nor did we see any difference in the expression of matrix 
metalloproteinase 9 (MMP9) (Figure 2.5).  
Discussion 
In the present study, we demonstrated an important role for myeloid MR 
during ischemic stroke using cell type-specific knockout and a model of focal 
cerebral ischemia. We found that deletion of MR from cells of myeloid lineage 
significantly reduced stroke infarct volume following MCA occlusion. Further, a 
reduction in activated microglia/macrophages was observed along with a 
concomitant decrease in pro-inflammatory markers associated with the CAM 
phenotype. In addition, there was a partial preservation of the AAM phenotype. 
These data indicate that MyMRKO confers neuroprotection by modulating the 
immune response to ischemic stroke. Furthermore, we identify myeloid cells, 
which includes macrophages and microglia, as critical targets for MR antagonists 
and MR-regulation of myeloid cells as a potential mechanism for neuroprotection 
exhibited in previous studies. 
To address the effect that myeloid MR has on the inflammatory response 
to stroke, we measured the expression of CAM and AAM markers following MCA 
occlusion. We observed infarct-induced MyMRKO suppression of TNF-α, IL-1β, 
MCP1, IL-6 and Mip1α, which are expressed principally by macrophages and are 
markers of classical macrophage activation. Several of the CAM markers such as 
MCP1, IL-1β, and Mip1α were highly suppressed by 5-, 5- and 3-fold changes, 
respectively. However, the expression of AAM markers, Arg1 and Ym1, was 
partially preserved in MyMRKO mice with both being suppressed by less than 2-
fold. The suppression of AAM markers was less than all of the CAM markers 
tested. This indicates there may be a higher ratio of AAM polarized myeloid cells 
within the brain and suggests that macrophage polarization may have an 
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important role in neurologic outcome. Other AAM markers that were previously 
found to be regulated by MR during cardiac inflammation such as Mrc1, Mgl1 and 
Fizz1 were not upregulated during ischemia. This is likely due to the fact that 
different phenotypes of AAM polarization can exist based on the external stimuli 
that activate macrophages or expression of these genes in other cell types. 
Immunohistochemical staining for Iba1 indicates a significant change in 
the macrophage/microglia response. However, Iba1 does not differentiate 
between macrophages and microglia, and it is difficult to differentiate the two cell 
types based on morphology. Changes in Iba1 staining were mainly confined to 
subcortical regions, although changes in infarct size are largely defined by 
differences in the cortex. This could indicate that MR control of the CAM/AAM 
phenotype, rather than increases in the total number of myeloid cells, are more 
important in determining infarct size in the cortex.  
There is evidence that microglia also adopt different functional phenotypes 
similar to the classical and alternative macrophage polarization.20, 21 However, 
microglia do not express LysM until they become activated, and even upon 
activation there is only partial gene recombination and deletion.22 Microglia 
containing LysM-Cre are able to undergo partial recombination during isolation 
and culturing, but we were unable to detect any suppression of MR expression in 
cultured microglia. This would suggest that resident macrophages or infiltrating 
myeloid cells might have a more dominant role in reducing inflammation and 
lesion size. It also remains to be determined whether MR activation can affect the 
population of circulating monocytes, which are recruited following ischemic 
stroke. Therefore, future studies aimed at identifying the individual contribution of 
monocytes, macrophages, and microglia are warranted.  
Iwanami et al. have shown that the MR antagonist eplerenone reduces 
macrophage associated oxidative stress following MCA occlusion.4 Further, high 
levels of aldosterone, a physiologic MR ligand, increase oxidative stress in 
circulating monocytes, as well as isolated macrophages.23, 24 Our data show that 
myeloid MR does not affect the expression of genes associated with oxidative 
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stress and the production of reactive oxygen species (ROS) 24 hours after 
ischemic stroke. However, many enzymes that generate ROS can be directly 
activated within minutes of ischemia-reperfusion. Furthermore, aldosterone is 
capable of activating NADPH oxidase by non-genomic mechanisms.25 We have 
not directly measured the levels of ROS and it could be possible that MR affects 
ROS production in this manner. 
Although mineralocorticoid excess clearly affects stroke, in a normal 
physiological setting where glucocorticoids are significantly higher than 
aldosterone, as mentioned above, myeloid MR is thought to be mainly occupied 
by glucocorticoids. Glucocorticoids have been implicated as important regulators 
of MR function in other tissues that lack 11β-HSD2, including the brain and heart. 
In a model of myocardial infarction, the glucocorticoid cortisol was shown to 
increase the size of infarction and myocyte cell death.26 This response was 
blocked by the MR antagonist spironolactone indicating potential actions of 
glucocorticoids on MR. Therefore, in our model of ischemic stroke, it is possible 
that glucocorticoids have a significant role in mediating the pro-inflammatory 
effects of myeloid MR. However, it is unclear how either aldosterone or 
glucocorticoids alter inflammation in macrophages and other myeloid cells. 
Future studies need to be aimed at understanding the mechanisms of myeloid 
phenotypic control by MR and whether MR is a direct transcriptional activator of 
pro-inflammatory genes.  
In summary, this study has identified a previously unknown role for 
myeloid MR activation during ischemic stroke. Using MyMRKO mice, we 
demonstrated that MR activation in myeloid cells exacerbates inflammation and 
alters the CAM/AAM inflammatory response to stroke. Moreover, these 
experiments indicate that MR control of immune cell function significantly affects 
stroke lesion size.  
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CHAPTER 3 
The Myeloid Mineralocorticoid Receptor During Experimental Ischemic 
Stroke: Effects of Model and Sex 
 
Abstract 
Background – Mineralocorticoid receptor (MR) antagonists have protective 
effects in the brain during experimental ischemic stroke, and we have previously 
demonstrated a critical role for myeloid MR during stroke pathogenesis. In this 
study, we explore both model and sex-specific actions of myeloid MR during 
ischemic stroke.  
Methods and Results – The MR antagonist eplerenone significantly reduced the 
infarct size in male (Control - 99.5 mm3, Eplerenone – 74.2 mm3, n = 8-12 per 
group), but not female (Control – 84.0 mm3, Eplerenone – 83.7 mm3, n = 6-7 per 
group) mice following transient (90 minute) middle cerebral artery (MCA) 
occlusion. In contrast to MR antagonism, genetic ablation of myeloid MR in 
female mice significantly reduced infarct size (MyMRKO - 19.2 mm3, Control - 
64.4 mm3, n=6 per group) after transient MCA occlusion. This was accompanied 
by significant reductions in inflammatory gene expression and neurological 
deficit. In contrast to ischemia-reperfusion, MyMRKO mice were not protected 
from permanent MCA occlusion. There were no significant differences in infarct 
size and inflammation after photothrombotic and intraluminal filament models of 
permanent occlusion.  
Conclusions – Here we demonstrate that MR antagonism is only protective in 
male mice during transient MCA occlusion, but genetic ablation of myeloid MR 
_______________________ 
This chapter represents a published article: Frieler, R.A., Ray, J.J., Meng, H., et 
al. The Myeloid Mineralocorticoid Receptor During Experimental Ischemic Stroke: 
Effects Of Model And Sex. J Am Heart Assoc. 2012 Oct;1(5):e002584.
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is protective in both male and female mice. They also highlight significant 
mechanistic differences in the role of myeloid cells in different models of stroke 
and confirm that specific myeloid phenotypes play key roles in stroke protection.  
Introduction 
Mineralocorticoid receptor (MR) activation is a contributing factor in the 
pathophysiology of a wide range of diseases. Elevated levels of aldosterone, a 
physiological MR activator, are known to induce hypertension, alter inflammation 
and fibrosis, and exacerbate cardiovascular diseases. Clinical, therapeutic 
interventions for the treatment of hypertension, heart failure, and post-myocardial 
infarction remodeling have successfully employed the use of MR antagonists.1, 2 
However, the benefit of this class of drugs may extend to the treatment of other 
cardiovascular diseases like ischemic stroke. In fact, the MR antagonists 
eplerenone and spironolactone are both markedly effective in reducing infarct 
size and neurological deficit following ischemic stroke in male rats and mice.3-5  
Despite the known protective effects of MR antagonists, the exact 
mechanisms of protection are not well understood. In addition to demonstrating a 
remarkable efficacy of MR antagonists to decrease mortality during heart failure, 
the RALES study also showed that these effects occur without altering blood 
pressure and in the absence of aldosterone excess.2 Furthermore, 
spironolactone and eplerenone protected rodents from stroke injury without 
affecting blood pressure.3, 5 However, new information has recently come to light 
as a result of cell-specific genetic ablation techniques allowing for localization of 
MR activity critical to the pathophysiology of disease.  
 We have previously identified MR as a regulator of macrophage activation 
and demonstrated that MR antagonists or myeloid MR knockout (MyMRKO) 
induces an alternatively activated macrophage (AAM) phenotype.6 Alternately, 
MR activation by aldosterone induces a pro-inflammatory, classically activated 
macrophage (CAM) phenotype. Macrophage phenotypes influences the outcome 
in cardiac remodeling after infarct,7, 8 and deletion of MR from myeloid cells 
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significantly reduced cardiac remodeling in response to NG-nitro-L-arginine methyl 
ester/angiotensin II administration.6 These studies demonstrated that MR 
activation in myeloid cells plays a critical role in the promotion of 
pathophysiological cardiac remodeling.  
The neuroprotective effects of MR antagonists have become the focus of 
many recent studies, and it is now known that MR activation in myeloid cells 
plays an important role during ischemic stroke. MyMRKO mice are significantly 
protected from ischemia-reperfusion injury in the brain, demonstrating the 
importance of myeloid cells as targets for MR antagonists during ischemic 
stroke.9 Previous studies also indicate that female rats lack responsiveness to 
MR antagonists;10 therefore we tested whether genetic myeloid MR ablation was 
protective in females during ischemic stroke. To further evaluate and characterize 
this neuroprotective phenotype, we also tested whether MyMRKO mice were 
protected in models of permanent middle cerebral artery (MCA) occlusion.  
Methods 
Mice  
 All animal procedures were performed in accordance with the Guide for 
the Care and Use of Laboratory Animals (NIH Publication no. 80–23) and were 
approved by the University Committee on Use and Care of Animals of the 
University of Michigan. Adult male and female mice weighing between 25-30 g 
were used. MyMRKO mice (MRflox/flox; LysMCre+/-) and littermate floxed controls 
(FC; MRflox/flox) on a C57BL/6 background were generated as described 
previously.6 Mice were maintained on standard laboratory chow (5001, LabDiet) 
and water ad libitum. Mice were administered eplerenone (Sandoz, Princeton, 
NJ) (160 mg/kg/day) in rodent chow (Harlan Teklad, TD.10030) for one week 
prior to experiments. 
Intraluminal Filament MCA Occlusion  
 MCA occlusion using the intraluminal filament method was performed as 
previously described.11 The mice were anesthetized with 1-3% isoflurane and a 
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6-0 silicon rubber-coated nylon monofilament (Docoll Corporation, CA) was 
inserted into the right internal carotid artery. Regional cerebral blood flow was 
monitored using laser Doppler flowmetry (Transonic BLF21) before and during 
monofilament insertion to verify MCA occlusion. Occlusion was defined as a 
reduction in cerebral blood flow to a level less than 20% of baseline. For 
ischemia-reperfusion studies, the suture was removed after 90 minutes and 
animals were euthanized 24 hours after suture removal. For permanent occlusion 
experiments, the suture remained tied in place until the animals were euthanized.  
Photothrombotic MCA Occlusion  
 For induction of photothrombotic stroke, the temporalis muscle was 
transected and the left MCA was exposed by drilling a 1 mm burr hole through 
the skull. A laser Doppler flow probe (Type N (18 Ga), Transonic Systems) was 
placed distal to the exposed MCA to monitor cerebral blood flow. A 3.5−mW 
green light laser (540 nm, Melles Griot) was directed at the MCA and rose bengal 
(Acros Organics) was injected intravenously (50 mg/kg). The relative tissue 
perfusion units (TPU) of the cerebral cortex was monitored continuously with a 
laser Doppler flowmeter (Transonic BLF21). Stable occlusion was defined as a 
drop in TPU to a level less than 20% of baseline for greater than 10 minutes.  
Measurement of Infarct Volume  
 All infarcts were analyzed using magnetic resonance imaging (MRI). 
Twenty-four and seventy-two hours after transient or permanent MCA occlusion, 
mice were anesthetized with 2% isoflurane/air mixture throughout MRI 
examination. Mice lay prone, head first in a 7.0T Varian Unity Inova MR scanner 
(183-mm horizontal bore, Varian, Palo Alto, CA) with the body temperature 
maintained at 37°C, using forced heated air. A double-tuned volume 
radiofrequency coil was used to scan the head region of the mice. Axial T2-
weighted images were acquired using a fast spin-echo sequence with the 
following parameters: repetition time (TR)/effective echo time (TE), 4000/60 ms; 
echo spacing, 15 ms; number of echoes, 8; field of view (FOV), 20x20 mm; 
matrix, 256x128; slice thickness, 0.5 mm; number of slices, 25; and number of 
 	  
	  
54 
scans, 1 (total scan time ~2.5 min.). The infarct volumes were analyzed using 
NIH ImageJ software (ver 1.43) by a blinded observer, and infarct volumes were 
corrected to account for brain swelling.12, 13 The following equation was used to 
calculate the corrected T2-lesion volumes:  
Corrected T2-lesion volume = TV - ((CV + (IV - LV)) x ((TV/2) / CV)) 
TV = total volume in both hemispheres, CV = contralateral volume, IV = 
ipsilateral volume, LV = lesion volume.  
Evaluation of Neurological Deficit  
 Neurological deficits were determined 24 hours after MCA occlusion. 
Neurological scores were assigned based on the following criteria: 0, no deficit; 
1, forelimb flexion and torso turning to the contralateral side when held by tail; 2, 
circling to contralateral side; 3, unable to bear weight on contralateral side; 4, no 
spontaneous locomotor activity.  
Gene Expression Analysis  
 mRNA expression was measured using quantitative reverse transcription–
polymerase chain reaction (qRT-PCR). Total RNA was extracted from frozen 
whole cerebral hemispheres using TRIzol reagent and then purified with the 
RNeasy Mini Kit (Qiagen). Purified RNA (1μg) was reverse transcribed to cDNA 
using an Applied Biosystems kit. qRT-PCR was performed using a Bio-Rad 
iCycler. The relative mRNA expression was quantified using the comparative 
method, and mRNA was normalized to β-actin. 
Immunohistochemistry  
 Mice were euthanized and transcardially perfused with heparinized saline 
(1 U/mL) and then 4% paraformaldehyde. The brains were removed and post-
fixed in 4% paraformaldehyde for 1 week. The cerebrum was then cut into 2-mm 
thick serial coronal sections. Sections were embedded in paraffin and cut into 10 
μm sections and mounted on a slide. Iba1+ microglia and macrophages were 
detected using goat polyclonal anti-Iba1 antibody (Abcam, ab5076) at a 1:300 
dilution on paraffin embedded sections. Immunoreactivity was visualized with an 
ABC kit (Vector Labs) using a biotinlyated rabbit anti-goat secondary antibody 
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and diaminobenzadine. Iba1+ cells were quantified and expressed as number of 
cells/field (40X objective). Two 40X fields were counted by a blinded observer in 
each anatomical region and averaged to obtain the number of Iba1+ microglia 
and macrophages. 
Statistics  
 Data are presented as mean ± SEM. Statistical comparison of mean 
values between groups was performed using the non-parametric, Mann-Whitney 
test and analyzed using Prism (version 5; GraphPad Software, Inc.), or by a two-
way ANOVA with a Bonferroni post-test as indicated. P < 0.05 was considered 
significantly different. 
Results 
Female MyMRKO mice are protected from transient MCA occlusion 
Previous studies indicate that MR antagonists are protective in male, but 
not female SHRSP rats during ischemic stroke.10 Similarly, we found that female 
mice also lack responsiveness to the MR antagonist eplerenone during transient 
MCA occlusion. Pretreatment with eplerenone significantly reduced the infarct 
size in male (Control - 99.5 mm3, Eplerenone – 74.2 mm3), but not female 
(Control – 84.0 mm3, Eplerenone – 83.7 mm3) mice (Figure 3.1A-B). Male 
MyMRKO mice are highly protected during ischemia reperfusion in the brain.9 To 
determine if a sexual dimorphic effect also exists in genetically ablated MyMRKO 
mice, we subjected female mice to transient MCA occlusion. We performed a 90 
minute transient MCA occlusion followed by 24 hours reperfusion, and the 
infarcts were assessed using T2-weighted MRI. Analysis of MRI scans showed a 
dramatic reduction in infarct size in female MyMRKO mice (Figure 3.2A). This is 
consistent with what we have observed in male mice. Quantification of infarct 
sizes using ImageJ software revealed a significant reduction in infarct size in the  
ischemic hemisphere of MyMRKO compared to floxed controls (FC) (Figure 
3.2B). This signifies a 70% reduction in total infarct size in the ischemic 
hemisphere (MyMRKO - 19.2 ± 8.3 mm3, FC - 64.4 ± 8.2 mm3, P = 0.001) (Figure  
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Figure 3.1. MR antagonism with eplerenone is protective in male, but not 
female mice during transient MCA occlusion. Representative MRI sections 
and infarct volumes from control and eplerenone treated (A) male and (B) female 
mice 24 hours after transient (90 minute) MCA occlusion. n = 6 - 12 per group.  
 
3.2C). The reduction in infarct size in MyMRKO mice was accompanied by a 
concomitant improvement in neurological function indicated by significantly lower 
neurological scores (MyMRKO - 0.5 ± 0.2, FC - 1.8 ± 0.4, P = 0.01) (Figure 
3.2D).  
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Figure 3.2. Infarct size and neurological deficit in female MyMRKO mice 
after transient MCA occlusion. (A) Representative MRI sections from FC and 
MyMRKO mice 24 hours after transient (90 minute) MCA occlusion. Infarct sizes 
in FC and MyMRKO mice represented as (B) fraction in ipsilateral hemisphere 
and (C) total infarct volume. (D) Functional outcome was assessed by scoring 
neurological deficit in mice after 24 hours. n = 6 per group. 
 
Female MyMRKO mice have a suppressed inflammatory response 
Since MR is a regulator of macrophage polarization, we analyzed the 
mRNA expression of genes induced in CAM and AAM phenotypes using qRT-
PCR. Female MyMRKO exposed to transient MCA occlusion exhibited a 
dramatic suppression in inflammatory gene expression compared to similarly 
treated FC female mice. The expression of pro-inflammatory, CAM genes (IL-1β, 
TNF-α, MCP1, and Mip1α) was significantly suppressed in ischemic 
hemispheres of MyMRKO mice when compared with FC (Figure 3.3A). We also 
examined a panel of genes (Arg1, Ym1, IL1RA, and F13a1) expressed by 
alternatively activated macrophages. The expression of Arg1 and Ym1 was 
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suppressed in MyMRKO mice (Figure 3B).  No statistically significant differences 
in IL1RA and F13a1 were detected (Figure 3.3B).  
 
Figure 3.3. Female MyMRKO mice have suppressed inflammatory gene 
expression after transient MCA occlusion. Gene expression of (A) pro-
inflammatory, CAM markers and (B) AAM markers 24 hours after transient (90 
minute) MCA occlusion. All genes were normalized to β-actin. *P < 0.05, **P < 
0.01 by 2-way ANOVA Bonferroni post-test. n = 5-6 per group. 
 
MyMRKO mice are not protected during permanent MCA occlusion 
MR antagonists have been shown to provide neuroprotection during both 
transient and permanent occlusion models of ischemic stroke. To evaluate the 
role of MyMRKO in conditions of permanent occlusion, we subjected MyMRKO 
and FC mice to MCA photothrombosis. Infarct sizes were assessed by MRI 24 
hours after MCA photothrombosis. Surprisingly, no significant differences in 
infarct volumes were observed between MyMRKO and controls in both male and 
female mice (Figure 3.4). Since a reduction in perfusion during permanent 
occlusion reduces infiltration of circulating inflammatory cells, we also assessed 
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the infarcts at 72 hours when more peripheral immune cells are recruited.14 An 
increase in infarct volume was observed at 72 hours due to infarct expansion, but 
there continued to be no differences in infarct size between MyMRKO and FC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Infarct size in MyMRKO mice after photothrombotic MCA 
occlusion. (A) Representative MRI sections from male MyMRKO mice 24 hours 
after MCA photothrombosis. Infarct sizes in (B) male and (C) female FC and 
MyMRKO mice represented as fraction in ipsilateral hemisphere and total infarct 
volume. n = 5-6 per group. 
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We previously observed a significant reduction in the number of Iba1+ cells 
(microglia and macrophages) in the infarct core in MyMRKO mice during 
transient occlusion.9 Therefore, we examined whether there were changes in 
microglia and macrophage numbers during permanent MCA photothrombosis.  
Significant increases in Iba1+ microglia and macrophages were present in the 
ipsilateral hemisphere of both MyMRKO and FC mice; however no differences 
were present between MyMRKO and FC (Figure 3.5). Similarly, no baseline 
differences were observed in the contralateral hemispheres.  
 
Figure 3.5. Immunohistochemical analysis of macrophages and microglia 
24 hours after photothrombotic MCA occlusion. (A) Representative 
photomicrographs of contralateral and ipsilateral hemispheres from FC and 
MyMRKO mice stained with microglia and macrophage immunoreactive Iba1 
antibody. (B) Quantification of Iba1 immunoreactive cells in the infarct core. n = 5 
per group. 
 
 To further evaluate the changes in the inflammatory response, we 
analyzed the CAM and AAM markers. The gene expression of CAM markers (IL-
1β, TNF-α, MCP1, and Mip1α) were all significantly increased in the ipsilateral 
hemisphere of MyMRKO and FC mice compared to the contralateral hemisphere, 
but no changes between groups were observed (Figure 3.6A). Similarly, no 
differences were observed in AAM markers between MyMRKO and FC mice 
(Figure 3.6B).  
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Figure 3.6. Expression of inflammatory markers in MyMRKO mice 24 hours 
after photothrombotic MCA occlusion. Gene expression of (A) pro-
inflammatory, CAM markers and (B) AAM markers 24 hours after MCA 
photothrombosis. All genes were normalized to β-actin. n = 6 per group. 
 
MR antagonists have not been tested in the photothrombosis stroke model 
and it is unknown whether they are protective in this model. Therefore we also 
tested the effect of MyMRKO during permanent MCA occlusion using the 
intraluminal filament model in which the MR antagonists are known to be 
effective at reducing infarct size. Consistent with the results from MCA 
photothrombosis, we found no differences in infarct size and neurological deficit 
between MyMRKO and controls 24 hours after permanent MCA occlusion using 
the intraluminal filament model (Figure 3.7). These data indicate that reperfusion 
is necessary for myeloid cell phenotypes to alter stroke outcome. 
 	  
	  
62 
 
Figure 3.7. Infarct size in MyMRKO mice after permanent MCA occlusion 
using the intraluminal filament model. (A) Representative MRI sections from 
male FC and MyMRKO mice 24 hours after permanent MCA occlusion. Infarct 
sizes in FC and MyMRKO mice represented as (B) fraction in ipsilateral 
hemisphere and (C) total infarct volume. (D) Functional outcome was assessed 
by scoring neurological deficit in mice after 24 hours. n = 5 per group. 
 
Discussion 
In the current study, we evaluated the role of myeloid MR in female mice 
and in multiple models of ischemic stroke. We found that male, but not female 
mice were protected from cerebral ischemia by pretreatment with the MR 
antagonist eplerenone. In contrast to MR antagonism, genetic ablation of MR in 
myeloid cells is neuroprotective in female mice. Like males, female MyMRKO 
mice were dramatically protected from transient occlusion and had highly 
significant reductions in infarct size, neurological deficit and inflammatory 
response. Furthermore, we also show that the neuroprotective phenotype in 
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MyMRKO mice exists during transient MCA occlusion, but not during permanent 
MCA occlusion. MyMRKO mice displayed no differences in infarct size and 
inflammation in MCA photothrombosis and intraluminal filament models of 
permanent occlusion.  
It has been well established that MR antagonists have protective effects 
and significantly reduce stroke lesion volume in male mice and SHRSP rats. The 
majority of experimental cardiovascular studies using animal models only report 
the use of male animals. The STAIR recommendations for performing preclinical 
stroke studies include using multiple models (permanent and transient occlusion) 
in both male and female subjects to better assess the viability of drugs for clinical 
translation.15 In accordance, we investigated the effects of the MR antagonist 
eplerenone during transient MCA occlusion in both sexes and found that it is 
protective in male, but not female mice. This is consistent with a previous report 
published by Rigsby and colleagues demonstrating that neuroprotection by MR 
antagonists does not extend to female rats.10 They found that non-ovarectomized 
and ovarectomized female rats lacked responsiveness to both spironolactone 
and eplerenone during ischemic stroke. Female SHRSP rats were also shown to 
have elevated levels of MR in the cerebral vasculature when compared to males, 
but it is not known whether this contributes to the sexual dimorphism of MR 
antagonists.  
MR antagonists have also been shown to display sexual dimorphism in 
their ability to reduce blood pressure. In a salt-induced hypertension model, the 
MR antagonist spironolactone was effective in reducing blood pressure in male, 
but not female Wistar rats.16 Similarly, intracerebroventricular injection of the MR 
antagonist RU28318 resulted in a reduced anti-hypertensive response in female 
rats compared to males.17, 18 Despite the differences in the likely mechanism of 
blood pressure lowering in these two models, females lacked responsiveness to 
MR blockade. The sexual dimorphic effects of MR antagonists have been 
suggested to be due to alternative drug metabolism in females, and it has been 
shown that the MR antagonist eplerenone is differentially metabolized in male 
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and female mice. Interestingly though, male rats have been shown to metabolize 
eplerenone more rapidly than females.19 Furthermore, this hypothesis is 
confounded by the observation that MR antagonists have beneficial effects in 
females during models of cardiac remodeling and cerebral aneurysm 
formation.20-22 Taken together, the available data suggest that the sexual 
dimorphic actions may be due to model-specific effects rather than differential 
drug metabolism.  
In contrast to MR antagonism, our studies show that genetic ablation of 
myeloid MR is protective in both male and female mice after transient MCA 
occlusion. Myeloid MR knockout significantly reduced infarct volume and 
suppressed inflammation while improving neurological function. These results 
indicate that there may be differential sexual dimorphism of MR antagonists in 
different cell types. In fact, MR clearly has effects in other cell types within the 
brain and cerebrovasculature, and MR overexpression in neurons has actually 
been shown to have beneficial effects during cerebral ischemia.23 It is possible, 
then, that sex-dependent differences in the expression and regulation of neuronal 
MR or in the intracellular metabolism of MR agonists or antagonists could play a 
role in sexually dimorphic responses to MR antagonists in stroke. The studies by 
Rahmouni and colleagues in which intracerebroventricular injections of MR 
antagonists exhibited reduced efficacy in females may indeed indicate that 
sexual dimorphism of MR antagonists exists in non-myeloid cell types in the 
brain.17 In light of these data, our studies indicate that myeloid-targeted drug 
delivery could be an effective strategy in the treatment of stroke. Modification of 
drugs to reduce passage across the blood-brain barrier could provide a means to 
target circulating cells without affecting other cell types in the brain. 
MR antagonists are protective in both transient and permanent MCA 
occlusion. In contrast, MyMRKO mice were protected during transient MCA 
occlusion, but not during models of permanent MCA occlusion. There were no 
differences in infarct size, macrophage/microglia recruitment, and inflammatory 
gene expression between MyMRKO and controls subjected to photothrombotic 
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stroke. Similarly, no differences in infarct size and neurological deficit were 
observed during permanent occlusion using the intraluminal filament model. Our 
finding that MyMRKO is protective in transient, but not permanent occlusion may 
provide critical insight into the mechanism of protection with myeloid-specific MR 
ablation and the role that myeloid MR plays during the pathophysiology of stroke. 
Several studies targeting inflammatory molecules (neutrophil elastase, 
CD11b/CD18, MMPs, ICAM-1) have also shown protective effects in transient, 
but not permanent occlusion.24-28 Our current experiments support the hypothesis 
that inflammatory cells make significant contributions to reperfusion injury and 
also demonstrate a key role for the macrophage lineage in this process.  
In permanent occlusion models of stroke, cerebral blood flow is not 
restored, and there is reduced and delayed inflammatory cell infiltration from the 
peripheral circulation. The supply of infiltrating cells from the periphery is 
dependent on the extent of collateral vasculature. Thus, much of the early 
inflammatory cell recruitment during permanent occlusion is due to resident 
immune cells within the brain parenchyma. This might suggest that 
neuroprotection in MyMRKO mice during transient occlusion is a result of 
modulating the trafficking of circulating myeloid immune cells rather than altering 
the activation phenotypes of microglia or macrophages within the brain 
parenchyma. However, temporal changes in macrophage activation states 
following ischemic stroke are largely unknown, and alterations in the balance of 
CAM and AAM phenotypes may be a critical factor in altering stroke severity. 
Female MyMRKO mice exhibited a suppression of both CAM and AAM markers 
24 hours after transient ischemia, but it will be important to examine the 
phenotypic changes in activation states at earlier time points. Suppression of 
some AAM markers in females was more significant than in males (described 
previously) and could reflect previously observed sexually dimorphic Th1/Th2 
immune responses.29-32 Since myeloid cells significantly contribute to reperfusion 
injury and oxidative damage, a reduction in inflammatory cell recruitment and/or 
decrease in CAM phenotypes could also reduce reperfusion injury. 
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  In conclusion, we demonstrate that genetic ablation of myeloid MR, but 
not MR antagonism is protective during transient occlusion in female mice. Our 
results further delineate the actions of myeloid MR during ischemic stroke and 
indicate that myeloid MR plays a more significant role in reperfusion injury. Thus, 
MR targeted drug development may be a feasible therapeutic intervention for 
stroke, particularly when combined with reperfusion strategies. 
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CHAPTER 4 
Probing the Mechanisms of Neuroprotection in Myeloid-Specific 
Mineralocorticoid Receptor Deficient Mice During Ischemic Stroke 
 
Abstract 
Background and Purpose — Mineralocorticoid receptor (MR) antagonists are 
neuroprotective in preclinical models of ischemic stroke, and myeloid MR has 
been identified as a critical modulator of stroke pathophysiology. In the present 
study, we probed the mechanisms of neuroprotection in myeloid-specific MR 
deficient mice and define a new role for MR in CD11c+ cells during stroke. 
Methods and Results — Myeloid-specific MR knockout mice were subjected to 
transient (90 minute) middle cerebral artery occlusion followed by reperfusion. A 
time course analyzing infarct development showed that MyMRKO mice had 
significantly reduced infarct size 2 hours after reperfusion. This was associated 
with a reduction in Mip1α and Ym1 gene expression, but not other major 
proinflammatory genes. MyMRKO mice also had decreased expression of 
vascular and thrombosis markers endothelin1 and Pai1, but analysis of cerebral 
tissue perfusion showed no differences between MyMRKO and controls during 0 
to 2 hours reperfusion.  
To assess the role of MR in dendritic cells, we used a CD11c-Cre line to 
delete MR from CD11c+ cells. Deletion of MR from CD11c+ cells significantly 
reduced infarct size and inflammatory gene expression 24 hours after 90 minute 
MCA occlusion. Furthermore, depletion of CD11c+ cells using CD11c-DTR mice 
resulted in increased infarct size after transient MCA occlusion. 
Conclusions —These data demonstrate that neuroprotection by myeloid MR 
deletion occurs very early during infarct development and significantly blocks
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infarct formation within 2 hours of reperfusion. In addition, these data indicate 
that MR may regulate dendritic cell function during stroke, and identify CD11c+ 
cells, possibly dendritic cells, as potential targets for MR antagonists.  
Introduction 
 Mineralocorticoid receptor (MR) activation has a pathological role in a wide 
range of cardiovascular diseases independent of its classical role in blood 
pressure control. MR antagonists have been used clinically to prevent the 
harmful effects of MR activation during cardiac remodeling,1, 2 and have also 
been found to be effective in many preclinical models of disease, including 
stroke.3-6 In stroke models, MR antagonists have been shown to decrease 
mortality, reduce infarct size, and decrease neurological deficit,3-6 although our 
understanding of the specific cell types involved is insufficient. Recent studies 
have delineated several new cell type-specific roles for MR in endothelial cells, 
smooth muscle cells, neurons, and macrophages, which may have important 
roles in stroke pathophysiology.7-10  
 In macrophages, MR has a pro-inflammatory role and is capable of 
regulating macrophage polarization. Activation of MR with aldosterone enhances 
pro-inflammatory responses associated with classically activated macrophage 
(CAM) phenotypes, where as MR antagonism or deletion induces an alternatively 
activated macrophage (AAM) phenotype.11 Importantly, myeloid MR has 
important pathological roles in cardiovascular disease, and myeloid MR knockout 
has been shown to be protective during cardiac remodeling, and more recently 
during ischemic stroke. We previously found that myeloid-specific deletion of MR 
dramatically reduced infarct size and inflammation after transient MCA 
occlusion.12 These effects were also shown to be model specific and 
neuroprotection was only present during ischemia-reperfusion, but not other 
models of permanent occlusion.13  
 The prolonged presence of CAM phenotypes is thought to prevent 
inflammatory resolution and exacerbate cardiovascular disease, where as AAM 
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phenotypes are largely thought to be protective. More recent studies have found 
that AAM/microglia phenotypes are present in the ischemic core, and are more 
abundant during early times when compared with CAM/microglia.14, 15 The 
influence of specific CAM and AAM phenotypes during stroke remains largely 
unknown, although there is some evidence to suggest that alternative activation 
may be beneficial.16 IL-4 is a potent inducer of AAM phenotypes, and IL-4 
deficiency has been shown to exacerbate stroke and increase the Th1/Th2 
ratio.17 Although MyMRKO mice have AAM polarizing effects, it is unclear 
whether these effects are important in the neuroprotective phenotype, and if so, 
the protective mechanisms of this AAM phenotype are unknown. 
 To identify the mechanisms of neuroprotection in MyMRKO mice, we 
performed a time course of infarct development and analyzed temporal changes 
in gene expression. In addition, we also examined other potential mechanisms of 
neuroprotection including regulation of vascular and thrombolytic function, and 
cerebral blood flow. Finally, we defined a role for MR in dendritic cells and other 
CD11c+ cells by generating a CD11c+ MR knockout using the CD11c-Cre line.  
Methods 
Mice  
 All animal procedures were performed in accordance with the Guide for 
the Care and Use of Laboratory Animals (NIH Publication no. 80–23) and were 
approved by the University Committee on Use and Care of Animals of the 
University of Michigan. Adult male and female mice weighing between 25-30 g 
were used. MyMRKO mice (MRflox/flox; LysM-Cre+/-), DCMRKO mice (MRflox/flox; 
CD11c-Cre+/-) and littermate controls (MRflox/flox) were on a C57BL/6 background. 
CD11c-DTR mice on a C57BL/6 background were from Jackson. For CD11c+-cell 
depletion, CD11c-DTR and littermate wild type mice received an intraperitoneal 
injection of diphtheria toxin (4 ng/g, Sigma Aldrich) 24 hours prior to MCA  
occlusion. Mice were maintained on standard laboratory chow (5001, LabDiet) 
and water ad libitum. 
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Bone Marrow Chimeras 
MyMRKO and control mice were myeloablated using an orthovoltage X-ray 
generator, and received a total body irradiation dose of 12 Gy administered in 2 
separate 6 Gy doses given 4 hours apart. Bone marrow derived cells (BMDCs) 
were flushed from femur and tibia bones, passed through a 40 µm cell strainer, 
and resuspended in PBS. After 24 hours, myeloablated mice were injected with 5 
million BMDCs via the retroorbital sinus, and 2 months were allowed for 
engraftment prior to experiments.  
Intraluminal Filament MCA Occlusion  
 MCA occlusion using the intraluminal filament method was performed as 
previously described.18 The mice were anesthetized with 1-3% isoflurane and a 
6-0 silicon rubber-coated nylon monofilament (Docoll Corporation, CA) was 
inserted into the right internal carotid artery. Regional cerebral blood flow was 
monitored using laser Doppler flowmetry (Transonic BLF21) before and during 
monofilament insertion to verify MCA occlusion. Occlusion was defined as a 
reduction in cerebral blood flow to a level less than 20% of baseline. For 
ischemia-reperfusion studies, the suture was removed after 90 minutes and 
animals were euthanized 24 hours after suture removal.  
Cerebral Blood Flow Measurements 
 Cerebral blood flow was assessed by monitoring cerebral tissue perfusion 
using a Doppler flowmeter. A laser Doppler flow probe (Type N (18 Ga), 
Transonic Systems) was placed above the lateral parietal bone distal to the MCA, 
and tissue perfusion was measured before, during and after MCA occlusion.  
Measurement of Infarct Volume  
 Infarcts were detected using triphenyltetrazolium chloride (TTC) for 1 hour 
and 2 hour time points. Mice were euthanized and brains were removed and cut 
into 1 mm sections using a brain matrix. Sections were place in 1% TTC for 20 
minutes at 37°C, and then fixed in 4% formaldehyde. The infarct volumes were 
analyzed using NIH ImageJ software (ver 1.43), and infarct volumes were 
corrected to account for brain swelling.  
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 Magnetic resonance imaging (MRI) was used to detect infarcts at the 24 
hour time points. Twenty-four hours after transient MCA occlusion, mice were 
anesthetized with 2% isoflurane/air mixture throughout MRI examination. Mice 
lay prone, head first in a 7.0T Varian Unity Inova MR scanner (183-mm horizontal 
bore, Varian, Palo Alto, CA) with the body temperature maintained at 37°C, using 
forced heated air. A double-tuned volume radiofrequency coil was used to scan 
the head region of the mice. Axial T2-weighted images were acquired using a 
fast spin-echo sequence with the following parameters: repetition time 
(TR)/effective echo time (TE), 4000/60 ms; echo spacing, 15 ms; number of 
echoes, 8; field of view (FOV), 20x20 mm; matrix, 256x128; slice thickness, 0.5 
mm; number of slices, 25; and number of scans, 1 (total scan time ~2.5 min.). 
The infarct volumes were analyzed using NIH ImageJ software (ver 1.43) by a 
blinded observer, and infarct volumes were corrected to account for brain 
swelling.19, 20 The following equation was used to calculate the corrected T2-
lesion volumes:  
Corrected T2-lesion volume = TV - ((CV + (IV - LV)) x ((TV/2) / CV)) 
TV = total volume in both hemispheres, CV = contralateral volume, IV = 
ipsilateral volume, LV = lesion volume.  
Gene Expression Analysis  
 mRNA expression was measured using quantitative reverse transcription–
polymerase chain reaction (qRT-PCR). Total RNA was extracted from frozen 
whole cerebral hemispheres using TRIzol reagent and then purified with the 
RNeasy Mini Kit (Qiagen). Purified RNA (1μg) was reverse transcribed to cDNA 
using an Applied Biosystems kit. qRT-PCR was performed using a Bio-Rad 
iCycler. The relative mRNA expression was quantified using the comparative 
method, and mRNA was normalized to β-actin. 
Microglia Isolation and Culture.  
 Isolation of cerebral microglia was performed as described previously. 
Briefly, 10-12 wk old mice FC and MyMRKO mice were euthanized and 
transcardially perfused with heparinized saline (1 U/mL). The cerebrum was 
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homogenized in ice cold PBS in a Tenbroeck homogenizer. The homogenate 
was then filtered through a 50 μm strainer and then resuspended in 70% isotonic 
Percoll. A 0/40/70% Percoll gradient was set up and centrifuged at 1200 x g for 
45 minutes at 20°C. The microglia containing fraction was then collected, 
resuspended in RPMI + 10% FBS and plated at a density of 2 x 105 
cells/mL/well. Cells were washed with PBS (+ calcium chloride, + magnesium 
chloride) after 2 hours to remove non-adherent cells and then incubated for 24 
hours at 37°C, 5% CO2. 
Statistics  
 A Kolmogorov-Smirnov test and normal quantile plots were used to 
determine if data were normally distributed. For normally distributed data, 
statistical comparison of mean values between groups was performed with the 
Student t test or by a two-way ANOVA with a Bonferroni post-test as indicated, 
and values are presented as mean ± SEM. Data that were not normally 
distributed were analyzed with the nonparametric Mann-Whitney test. All 
statistical analysis of data was performed in GraphPad Prism (version 5; 
GraphPad Software, Inc). P < 0.05 was considered significant.  
Results 
Neuroprotection by MyMRKO occurs during early infarct development 
 To define the critical times at which myeloid MR contributes to stroke 
pathology, we performed a time course analyzing infarct development in both 
MyMRKO and controls. After transient 90 minute MCA occlusion, TTC staining of 
cerebral sections revealed that neither MyMRKO nor controls had significant 
infarction after 1 hour reperfusion (Figure 4.1). By 2 hours reperfusion, control 
mice had dramatically increased infarct volume compared to MyMRKO mice. 
Moreover, the infarct volume in control mice was comparable to the infarct 
volume after 24 hours reperfusion, indicating that infarct development occurs 
very quickly. MRI and TTC measurement of infarct volume have previously been 
shown to be equivalent.19  
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Figure 4.1. Time course of infarct development in MyMRKO mice. Transient 
ischemia was induced by 90 minute MCA occlusion, and infarcts were analyzed 
by TTC staining at 1 and 2 hours reperfusion, and by T2-weighted MRI scans at 
24 hours reperfusion. Indirect infarct volume was quantified from serial sections 
or scans in each group. n = 3-7 / group. *P < 0.05. 
 
 We next performed a time course to determine the role of myeloid MR in 
the temporal regulation of inflammatory gene expression. After 1 hour 
reperfusion, expression of proinflammatory genes TNF-α, IL-1β, and Mip1α were 
increased, but no differences between MyMRKO and controls were present. At 2 
hours reperfusion, TNF-α and IL-1β remained increased in both groups, however, 
Mip1α was significantly decreased compared to controls (Figure 4.2). In addition, 
expression of the alternatively activated macrophage marker Ym1 was also 
significantly increased in controls, but not in MyMRKO mice.  
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Figure 4.2. Temporal analysis of gene expression in MyMRKO mice. Gene 
expression of inflammatory markers (IL-1β, TNF-α, and Mip1α) and of the 
alternative macrophage marker Ym1 at 1, 2, and 24 hours after transient 90-
minute MCA occlusion. All genes were normalized to HPRT. n = 3-5 per group. 
*P < 0.05. 
 
 Analysis of vascular and fibrinolysis markers showed that the expression 
of plasminogen activator inhibitor (Pai1) and endothelin (Edn1) were also 
significantly suppressed 24 hours after reperfusion (Figure 4.3).  
MyMRKO does not alter cortical cerebral blood flow in MCA territory after 
transient ischemia  
 Since differences in the expression of vascular and thrombosis markers 
were noted, we determined whether MyMRKO alters cerebral blood flow during 
early times when neuroprotection occurs. After occlusion of the MCA, cerebral 
tissue perfusion in the MCA territory dropped to less than 25% of baseline in both 
MyMRKO and control mice (Figure 4.4). Upon removal of the intraluminal 
filament, tissue perfusion slowly increased and was up to 80% of baseline 
perfusion after 60 minutes of reperfusion. No significant differences in tissue 
perfusion were detected between MyMRKO and controls during ischemia or 
reperfusion.  
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Figure 4.3. Gene expression of fibrinolytic and vascular genes. Analysis of 
gene expression of fibrinolytic and vascular genes was performed 24 hours after 
transient MCA occlusion. All genes were normalized to β-actin. n = 4 per group. 
*P < 0.05, **P < 0.01.  
 
 
              
Figure 4.4. Effect of MyMRKO on cerebral blood flow during transient MCA 
occlusion. Regional cerebral tissue perfusion was measured in the MCA territory 
before, during and after 90 minute MCA occlusion. n = 5 per group.  
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Contribution of bone marrow-derived and resident myeloid cells in the 
neuroprotective phenotype 
 Previous studies indicate that LysM-driven Cre expression is very low in 
unactivated microglia and does not result in complete recombination even with 
activating stimuli. In isolated microglia from MyMRKO mice, we detected no 
suppression of MR message (Figure 4.5A), even after ischemic stroke (Figure 
4.5B). To determine if LysM-Cre-mediated recombination of the floxed MR allele 
occurs in activated microglia during ischemic conditions, we isolated microglia 
from MyMRKO and control mice that received 90 minute MCA occlusion and 2 
hours reperfusion. PCR to detect the null allele revealed minimal recombination 
in isolated microglia (Figure 4.5C).  
 
 
Figure 4.5. Lack of MR deletion in microglia from MyMRKO mice. Gene 
expression of MR was measured in isolated microglia in the absence of stroke 
(A), and 2 hours after transient 90 minute MCA occlusion (B). PCR was used to 
detect recombination of the floxed MR allele in genomic DNA isolated from 
microglia that received transient MCA occlusion (C).  
 
 To further define the contribution of resident and circulating myeloid cells, 
bone marrow chimeras were generated. Myeloablated control and MyMRKO 
mice received either control or MyMRKO marrow (FC > FC, KO > KO, FC > KO, 
KO > FC). After 2 months engraftment of donor marrow, mice received 90 minute 
MCA occlusion and infarcts were analyzed by T2-MRI after 24 hours reperfusion. 
No differences in infarct volumes were detected in mice that received transplant 
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of MyMRKO into control (KO > FC) and control into MyMRKO (FC > KO) (Figure 
4.6). Surprisingly, control mice that received marrow from control donors (FC > 
FC) had similar size infarcts as MyMRKO mice that received marrow from 
MyMRKO mice (KO > KO) indicating that the neuroprotective phenotype was lost 
after irradiation and bone marrow transplant. 
 
                
 
Figure 4.6. Effect of myeloid MR bone marrow chimeras during ischemic 
stroke. Infarct volume of bone marrow chimera mice analyzed 24 hours after 
transient 90 minute MCA occlusion and assessed by T2-MRI.  
 
MR modulates stroke pathology through regulation of CD11c+ cells 
 Dendritic cells are present in the brain, and studies have indicated that MR 
has modulatory effects in dendritic cell function. In order to further delineate the 
cell-specific effects of MR antagonists, we generated CD11c+-cell MR knockout 
(DCMRKO) mice using the CD11c-Cre and then subjected them to transient MCA 
occlusion. After 90 minute MCA occlusion and 24 hours reperfusion, infarct 
volumes were analyzed by T2-weighted MRI. Compared to controls, DCMRKO 
mice had a modest, statistically significant decrease in infarct size (Figure 4.7).  
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Figure 4.7. DCMRKO mice have reduced infarct size during ischemic 
stroke. (A) Representative MRI sections from control and DCMRKO mice 24 
hours after transient (90 minute) MCA occlusion. (B) Quantification of infarct 
sizes in FC and DCMRKO mice. n = 8-11 / group. *P < 0.05. 
 
 
 
Figure 4.8. DCMRKO mice have suppressed inflammatory gene expression 
during ischemic stroke. Relative gene expression of inflammatory markers (IL-
1β, TNF-α, IL-6, and Mip1α) and anti-inflammatory and alternative markers (IL-
10, Ym1) were measured by qRT-PCR 24 hours after transient 90 minute MCA 
occlusion. *P < 0.05, **P < 0.01. 
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 Analysis of gene expression revealed selective suppression of pro-
inflammatory genes. IL-1β and IL-6 were significantly decreased in DCMRKO 
mice, where as no differences were detected in TNF-α and Mip1α (Figure 4.8).  
The alternatively activated macrophage marker Ym1 was also significantly 
suppressed in DCMRKO mice compared to controls, and a non-significant 
decrease in mean of IL-10 was noted.  
Depletion of CD11c+ cells increases infarct size after ischemic stroke 
 To elucidate the role of dendritic cells and other CD11c+ cells in ischemic 
injury, we employed the CD11c-DTR mouse line. CD11c-DTR and littermate wild 
type mice were treated with diphtheria toxin 24 hours prior to 90 minute MCA 
occlusion. Analysis of infarct by T2-weighted MRI revealed that dendritic cell 
depletion significantly increased infarct size 24 hours after reperfusion (Figure 
4.9).  
                              
  
Figure 4.9. CD11c+ cell depletion increases infarct size during ischemic 
stroke. Quantification of indirect infarct volume in WT and CD11c-DTR mice 24 
hours after transient 90 minute MCA occlusion. n = 4-6 per group. **P < 0.01. 
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ipsilateral cerebral hemispheres in CD11c-DTR mice (Figure 4.10A). The 
expression of proinflammatory genes TNF-α and IL-1β was significantly 
increased in the ipsilateral hemisphere of WT and CD11c-DTR mice compared to 
the contralateral hemisphere, although no differences were detected in the 
ipsilateral hemisphere between the groups (Figure 4.10B). CD11c+-cell depletion 
selectively upregulated the expression of the alternative activation marker Ym1 in 
both contralateral and ipsilateral hemispheres, but had no effect on Arg1 and 
IL1Ra (Figure 4.10C).  
   
  
 
Figure 4.10. CD11c+ cell depletion does not alter expression of major 
inflammatory genes during ischemic stroke. Expression of CD11c (A), 
proinflammatory markers (B), and markers of alternative activation (C) as 
determined by qRT-PCR 24 hours after transient MCA occlusion. All genes were 
normalized to β-actin. n = 4-6 per group. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Discussion  
 In the present study, we sought to identify the pathological role of myeloid 
MR activation during stroke by probing the mechanisms of neuroprotection in 
MyMRKO mice. To help identify potential pathological mechanisms, we first 
performed a time course to identify the critical time frame when neuroprotection 
occurs. Surprisingly, MyMRKO mice exhibited significant reduction in infarct size 
after only 2 hours reperfusion. This indicates that myeloid cells are capable of 
influencing stroke pathology much earlier than originally thought.  
 In addition, after 2 hours reperfusion the infarct volume in control mice was 
nearly as large, and not significantly different from the infarct volume at 24 hours. 
Although two different methods, TTC and MRI, were used for comparison of 
infarct size in this time course and may account for some minor differences, other 
studies have found that T2-MRI and TTC analysis of infarcts at 24 hours produce 
similar results.19 Since the infarct in this model is largely formed after 2 hours, 
this may suggest that many of the published neuroprotective strategies could be 
affecting stroke pathophysiology very early on, and that analysis of much early 
time points could be helpful in identifying the mechanisms of protection.  
 Inflammation and immune cells can profoundly impact coagulation and 
cerebral blood flow. Since the neuroprotective effects in MyMRKO mice are 
occurring very early on, we addressed whether MyMRKO influenced changes in 
cerebral blood flow immediately after reperfusion. We did not see any differences 
in cerebral blood flow between control and MyMRKO mice, although we cannot 
definitively rule this out as a potential mechanism of neuroprotection. We 
measured cortical perfusion of the core MCA territory, but changes might be 
occurring in subcortical and peripheral regions, and within microvessels that are 
not detectable by laser Doppler flowmetry. Iwanami et al. found that MR 
antagonists significantly increased cerebral blood flow in peripheral, but not core 
regions of the MCA territory within 1 hour after MCA occlusion.4 A more thorough 
analysis of cerebral blood flow with improved sensitivity using MRI or SPECKLE 
would help clarify whether MyMRKO induces changes in blood flow.  
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 We found that Pai1 and Edn1 were significantly decreased in MyMRKO, 
which might indicate that control mice have a more pro-thrombotic state. During 
cerebral ischemia-reperfusion injury, microthrombi can form during reperfusion 
and can occlude cerebral vessels and impair cerebral blood flow. Deficiency in 
clotting factors has been shown to protect against ischemia-reperfusion 21. 
Several reports have also shown that aldosterone induces a prothrombotic state 
and is associated with increased oxidative stress, increased Pai1 expression, 
and enhanced thrombus formation.22-24 Systemic administration of spironolactone 
has been shown to suppress Pai1 levels,25 and although the specific 
mechanisms are not well defined, one study suggests a role for mononuclear 
cells.23 
 To address the issue of whether circulating or resident microglia are 
critical mediators of the neuroprotective phenotype in MyMRKO mice, we 
generated bone marrow chimeras. Unexpectedly, we found that myeloablation 
and bone marrow transplant prevented the neuroprotective phenotype in 
MyMRKO mice. While it is known that irradiation to the brain can cause 
inflammation and can result in microglia activation and repopulation by bone 
marrow-derived precursors, it is not fully understood how myeloablation and 
subsequent repopulation of bone marrow niches affects specific myeloid 
phenotypes. Therefore, further studies will be necessary to understand the 
important mechanisms of myeloablation and bone marrow transplant that abolish 
protection in MyMRKO mice. 
 To expand our knowledge of MR regulated cells in stroke, we identified a 
role of MR in CD11c+ cells using a CD11c-Cre line. We found that MR deletion in 
CD11c cells significantly reduced infarct volume and reduced inflammatory gene 
expression compared to controls. CD11c-Cre is reported to have significant 
recombination in dendritic cells, while having only minimal recombination in other 
myeloid cells. Therefore these data may highlight an important role for MR in 
regulating dendritic cell phenotype during stroke. However, some populations of 
macrophages also express CD11c, and it is possible that the phenotype reflects 
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targeting of CD11c+ subset of macrophages. A more thorough analysis of MR 
function in dendritic cells both in vitro and in vivo is required in order to better 
understand the potential role in stroke.  
 Dendritic cells are present in the injured brain, and are known to influence 
other myeloid cells during disease. To test the role of dendritic cells in stroke, we 
used a CD11c-DTR line to transiently deplete dendritic cells during stroke. Here 
we found that depletion of CD11c+ cells significantly increased infarct size, but 
had no effect on inflammatory gene expression with the exception of Ym1. While 
this may indicate that dendritic cells are necessary for an effective immune 
response, these results may also be confounded by a systemic neutrophilia, 
which occurs after CD11c+ cell depletion.26 Neutrophils are known to be involved 
in stroke pathogenesis, and it is possible that increased infarct size could be due 
to an enhanced neutrophil response.  
 In conclusion, these data provide evidence of a pathological role for 
myeloid MR during early infarct development. Further, these data indicate that 
MR may regulate dendritic cell function during stroke and identify CD11c+ cells as 
potential targets for MR antagonists.  
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CHAPTER 5 
Discussion 
 The work presented in this dissertation describes for the first time a 
pathological role for the myeloid mineralocorticoid receptor (MR) during ischemic 
stroke. It has been previously shown that MR antagonists are protective in 
preclinical models of stroke,1, 2 but the important target cells have not been 
elucidated in the context of ischemic stroke. Since we previously found that MR 
has a proinflammatory role in macrophages and regulates macrophage 
phenotype,3 we hypothesized that MR activation in myeloid cells promotes 
inflammation-induced stroke damage and inhibition of myeloid MR is a 
mechanism for the beneficial effects of MR antagonists during stroke. To test this 
hypothesis, we used myeloid-specific MR deficient mice and subjected them to 
models of ischemic stroke. These data represent the first work to use genetic 
ablation to delineate cell-specific targets for MR antagonists during stoke.  
 In this dissertation, we have demonstrated several important findings: 1) 
myeloid-specific deletion of MR ameliorates stroke damage, 2) neuroprotection 
by myeloid MR deficiency occurs early during infarct development, 3) 
neuroprotection by myeloid MR deficiency is model-dependent and is protective 
in transient, but not permanent MCA occlusion, 4) myeloid MR deficiency is 
protective in both male and female mice, which contrasts the sexual dimorphic 
effects of MR antagonists during stroke where neuroprotection is only detected in 
male mice, and 5) genetic deletion of MR in CD11c+ cells is protective during 
ischemic stroke.  
 In support of our hypothesis, we found that myeloid MR knockout 
(MyMRKO) significantly blocked infarct development, reduced neurological 
deficit, and suppressed inflammation during transient MCA occlusion. This 
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provides evidence that MR has a pathological role in ischemic stroke by 
regulating myeloid cell phenotype. Since macrophages in MyMRKO mice have 
an enhanced AAM phenotype, we initially hypothesized that MyMRKO would 
protect against stroke by regulating macrophage polarization. While the 
protective effect of MyMRKO does provide some support for a beneficial role for 
AAM phenotypes during stroke, the specific myeloid cell types involved have not 
been defined. Some of the AAM markers were partially preserved during stroke, 
although they were not significantly upregulated compared with controls. Without 
a thorough phenotypic analysis of isolated macrophages, it is difficult to 
speculate on the role that regulation of macrophage polarization has in the 
neuroprotective phenotype.  
 A surprising, but significant finding of this work was that infarct formation 
occurs very rapidly within two hours of reperfusion in the transient MCA occlusion 
model. Further, this corresponds to the critical window of neuroprotection seen in 
MyMRKO. This is valuable to our understanding of the pathophysiology since it 
establishes that studies analyzing stroke volume at twenty-four hours are not 
studying the most critical time period in this model. It also identifies the window 
during which myeloid MR affects stroke pathophysiology. These results allow us 
to focus our search for potential neuroprotective mechanisms to a very narrow 
time frame. We were able to identify specific inflammatory genes that were 
selectively down regulated during early infarct development, and a more 
thorough investigation into the specific roles of these genes might help us define 
critical myeloid functions. This time frame also highlights the importance of 
myeloid cells during early infarct formation. Although a larger presence of 
immune cells is apparent after twenty-four hours, this suggests that immune cell 
regulation during early times has the most significant effects on the evolution of 
infarct development. This early effect might also suggest a role for MR in 
microglia, but we were unable to detect MR knockout in microglia, which does not 
support the involvement of microglia.  
	   92 
 The finding that MyMRKO is protective in transient, but not permanent 
MCA occlusion might also highlight some insight into the mechanisms of 
neuroprotection. Other studies targeting immune cells have also found similar 
model-dependent effects where neuroprotection is only detected during transient 
ischemia.4, 5 One of the obvious differences between these models is the 
restoration of blood flow. Reperfusion allows blood-borne immune cells rapid 
access to the cerebral vasculature in ischemic regions, whereas permanent 
occlusion of the MCA prevents immune cells from immediately reaching these 
regions. A major difference in the pathological mechanisms of these models is 
the presence of reperfusion injury during transient MCA occlusion. Immune cells 
are known to contribute significantly to reperfusion injury through the release of 
inflammatory cytokines and generation of reactive oxygen species. Further 
studies to determine if MR regulates reactive oxygen species generation in vitro 
and in vivo will provide information about whether this is a potential mechanism.  
 MR antagonists are sexually dimorphic is several disease models,6-8 and 
have been shown to be effective in males but not females during experimental 
stroke.9 The sexual dimorphism of MR antagonists appears to be model 
dependent, since some studies have found MR antagonist are effective in both 
males and females. MR antagonists do not exhibit sexually dimorphic 
antihypertensive effects in humans, although the cardioprotective effects seen in 
the RALES and EPHUSUS studies were not analyzed for sexual dimorphism.10, 11 
In our studies, we found that in contrast to MR antagonists, MyMRKO is 
protective during transient MCA occlusion in both male and female mice. 
Although the mechanisms for these effects are unknown, our results suggest that 
specific targeting of myeloid MR might be a strategy to overcome potential sexual 
dimorphism.  
 Finally, we provide evidence of a pathological role for MR in CD11c+ cells. 
We found that genetic deletion of MR in CD11c+ cells was protective during 
ischemic stroke. CD11c+-MR knockout significantly reduced infarct size and 
suppressed the inflammatory response after transient MCA occlusion. This may 
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indicate an important role for MR in regulating dendritic cell function, although it 
could also reflect important roles by other CD11c+ cell types such as certain 
macrophage subsets. It also remains unclear if there is overlap between the 
myeloid cells altered using the LysM-Cre and the CD11c-Cre used in these 
different experiments. 
Future studies to identify mechanisms of neuroprotection  
 We have delineated a new role for MR in myeloid cells during stroke, but 
there is still much to be known. In MyMRKO mice, we used LysM-Cre, which 
results in recombination in several myeloid cells including monocytes, 
macrophages, neutrophils, myeloid dendritic cells, and other granulocytes. In the 
myeloid lineage, most studies have focused on the role of MR in monocytes and 
macrophages, and even in these cell types, data is limited. We hypothesized that 
neuroprotection in MyMRKO mice is a result of altered monocyte and 
macrophage function because of our understanding of MR in these cell types. 
However, it is possible that MR has an important role in other myeloid cells. The 
information about the role of MR in neutrophils is limited, although one study 
found that aldosterone suppressed NF-κB activation and proinflammatory 
cytokine production in neutrophils.12 While this suggests that MR has a role in 
neutrophil function, it would not support a neuroprotective role for neutrophils in 
MyMRKO mice. The use of a more specific neutrophil Cre line might also provide 
more direct evidence in vivo,13 and is one avenue that we are currently pursuing.  
 One approach to understanding the involvement of other potential myeloid 
cell types is to study the functional responses of MR activation and inhibition in 
vitro. This could provide some general functional information that could be further 
explored in vivo. An alternative approach is to analyze the kinetics of leukocyte 
trafficking during stroke, and identify changes in specific leukocyte populations in 
the brain. The use of FACS analysis could be very helpful in identifying 
differences in cell numbers as well as for sorting specific cell types for phenotypic 
analysis. The presence or absence of specific cells might help identify changes in 
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recruitment and trafficking of cells, and might also eliminate others if they are not 
present at the early times during which we see neuroprotection. Comparing 
temporal changes in leukocytes with changes in gene expression will likely 
further our understanding.  
 The role of MR in the generation of ROS might also be an important 
pathological mechanism. Aldosterone has been shown to induce oxidative stress 
in monocytes and macrophages,14, 15 and MR antagonism decreases free radical 
production in rodent models of stroke.2, 16 Although we did not find differences in 
gene expression of oxidative related genes, MR has been shown to regulate 
NADPH oxidase activity through non-genomic mechanisms.17 The dependence 
of neuroprotection on reperfusion is also supportive of a role in the regulation of 
oxidative stress. Finally, since we detected changes in vascular and fibrinolysis 
genes, the use of more sensitive technologies to study cerebral blood flow could 
uncover changes in microthrombi formation and fibrinolysis that might account for 
early neuroprotective effects. 
Defining the important cell-specific effects of MR during stroke 
 Through the use of conditional knockout technology, we have identified 
important pathological roles for MR in myeloid cells and CD11c+ cells during 
stroke. Compared to MR antagonists, MyMRKO results in a much greater 
decrease in infarct size. This may reflect the multiple mechanisms of 
pharmacological control of MR antagonists in various cell types or the degree of 
inhibition, which may be more complete by genetic deletion. MR is expressed in a 
wide range a cell types, many of which also likely have unique roles in regulating 
cell function during stroke. Of particular importance to stroke, MR has been found 
to regulate neurons, astrocytes, smooth muscle cells and endothelial cells in vitro 
and in some case in vivo.18-24 Results from these studies suggest that MR 
activation in these cell types will have harmful effects during stroke, with the 
exception of neurons. Overexpression of MR in neurons has been found to be 
protective in a model of focal cerebral ischemia.25 Further delineation of the role 
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of MR in other cell types will provide a better understanding of the important MR 
target cells and may aid in the development of novel therapeutic strategies.  
 Although our understanding of MR in specific cell types is limited, the 
therapeutic benefit of MR antagonists in stroke models likely represents the 
summation of beneficial and detrimental effects in numerous cell types. The 
increased effect size in MyMRKO mice suggests that specific targeting of myeloid 
cells might have greater therapeutic potential. The use of synthetic nanoparticle 
carriers has been employed for targeted drug delivery to phagocytic cells.26, 27 If 
macrophages or phagocytic cells are in fact the critical MR-regulated myeloid cell 
type, specific targeting of these cells might be a more attractive therapeutic 
option, and may provide superior efficacy compared to conventional systemic 
delivery of MR antagonists. This would provide a means to specifically target MR 
in phagocytic cells where MR is known to have harmful effects, while sparing 
critical protective function in neurons. In addition, cell-specific drug delivery might 
also be a useful strategy to circumvent the potentially sexually dimorphic effects 
of MR antagonists.  
Therapeutic potential of immune cell phenotypes in disease  
 A large number of neuroprotective agents targeting inflammation and 
immune cells have been developed and have been found to be beneficial in pre-
clinical, animal models of ischemic stroke. To date, none of these have translated 
to clinical use. Many preclinical studies have successfully blocked inflammatory 
signaling and leukocyte adhesion or recruitment during stroke and found 
significant benefit, but clinical trials targeting CD11b, ICAM-1, and IL-1 receptor 
were ineffective.28-30 While there is some evidence for technical immunoreactivity 
issues in the ICAM-1 trial, the lack of efficacy in others reflects the need for a 
better understanding of the important differences in the pathophysiology between 
animals and humans. One complication is that mice and humans have 
significantly different immune systems, which is event by simple comparison of 
the relative ratios of leukocytes in the circulation.31 Despite these differences, 
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inflammation and immune cells are present in both animal and human models of 
stroke, and have important pathological roles.  
 Dynamic interplay between resident and blood-borne immune cell and the 
neurovascular unit can have pathophysiological roles in stroke, but immune cells 
are necessary for normal brain function and reparative function. Therefore, 
simply ablating macrophages and microglia is not beneficial in stroke and other 
models, likely because it eliminates important phagocytic roles of both resident 
and blood-borne cells. In contrast to inhibiting leukocyte recruitment and 
adhesion, the emerging concept of enhancing or modulating immune cell 
phenotypes has come into play. Several studies have found that adoptive 
transfer of protective cell types might be a potential therapeutic strategy. For 
example in several models of cardiovascular disease including hypertensive 
cardiac remodeling, myocardial infarction, and more recently stroke, adoptive 
transfer of Tregs has been shown to provide protective effects.32-35 Tregs secrete 
IL-10 and TGF-β, which can suppress immune cell responses and promote 
resolution of inflammation. However, more recently the adoptive transfer of Tregs 
were found to promote AAM phenotype during myocardial infarction, and it was 
speculated that this may be a mechanism of protection.36  
 Adoptive transfer of alternatively activation macrophages might also be a 
protective strategy. A recent study found that adoptive transfer of IL-4-induced 
AAMs did not reduce neurological deficit during ischemic stroke.37 However, the 
adoptive transfer was performed four days after transient MCA occlusion at which 
point the infarct is largely formed and treatment is unlikely to have an effect on 
infarct development. Adoptive transfer of AAMs during early times of infarct 
formation may have much greater therapeutic potential and is more likely to 
modulate immune cell-induced stroke damage. A phase I clinical trial is currently 
underway to test the therapeutic potential of autologous AAM treatment during 
stroke.  
 Our results suggest that the use of MR antagonists might be a viable 
means to regulate myeloid cell phenotype in stroke. Importantly, MR antagonists 
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are used clinically, and blood pressure-independent, cardioprotective effects 
have been shown during heart failure. While this is favorable in assessing the 
potential for clinical translation during stroke, no trials have been completed 
which demonstrate efficacy. 
Importance of macrophage phenotypes in disease 
 Our understanding of the function of macrophage phenotypes and the 
temporal composition of polarized phenotypes during disease formation and 
progression is still underdeveloped. In most studies, the kinetics of the changing 
environment and population of cells are not evaluated by looking only at a single 
time point. In experimental stroke models, most studies focus on late time points 
at twenty-four hours or later, when the critical process may be remote from the 
time point analyzed. Macrophages with different phenotypes play different roles 
during the evolution of disease and response to injury. Without understanding the 
progression in the pathophysiology, the conclusions about the process will be 
unreliable. While this will require considerable investment, it is critical to 
advancing the field. During stroke, studies analyzing the temporal changes in 
macrophage phenotypes are limited. One study found that AAM markers peak 
three to five days after stroke, whereas some CAM markers progressively 
increase for up to two weeks after stroke.38 However, this study is limited by its 
analysis of CAM/AAM markers from brain homogenates rather than isolated 
macrophages. The work presented in this dissertation indicates that macrophage 
phenotypes might have important functional roles during much early times.  
 Understanding the role of monocyte/macrophage lineage in the dynamic 
disease initiation and progression is also critically dependent on understanding 
the genes that are functioning to alter phenotype. We currently have markers that 
identify cell types with little understanding of the important phenotype. Even 
arginase, which was an early-recognized marker of AAM, can be beneficial,39 or 
detrimental,40 depending on the system. Therefore, specific functions need to be 
identified for the genes in AAMs that contribute to the beneficial (or detrimental) 
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effects in cardiovascular disease. Initially, investigators will have to rely on 
markers to identify the polarization cell types. Then by kinetic correlation with the 
functional changes in the lesions occurring with the presence of the subtypes, 
testable hypotheses about the function can be generated. By comparing the 
expression profile of AAM subtypes with the functional changes in disease, 
specific genes that are critical to the beneficial effects can be identified. 
Ultimately, the ability to pharmacologically manipulate macrophages may be 
understood as an important part of both current therapies (as we define the 
mechanisms of drugs) and the development of new therapeutic strategies.  
Mechanisms of functional control of macrophage phenotype 
 The mechanisms controlling macrophage phenotype, including the 
interaction of cytokines with nuclear receptors and the activation mechanisms of 
nuclear receptors is complex and not well defined. Although there appears to be 
a reciprocal relationship between the CAM and AAM, the wide variety of AAM 
phenotypes shows that there is specific regulation with each manipulation. The 
possible mechanisms include relief of inhibition of expression by removal of 
factors such as the PPARs, suppression of NF-κB, as well as direct stimulation 
by nuclear factors of AAM genes. During stroke, macrophage phenotype is likely 
regulated by a wide array of inflammatory cytokines and other signaling 
molecules. MR represents one of many mechanisms of induction for 
proinflammatory genes, and similarly there are many signaling pathways for 
induction of AAM genes. Unfortunately, due to the lack of suitable antibodies, the 
elucidation of MR target genes has been problematic. Therefore, it is unknown if 
MR directly binds to the promoters of the pro-inflammatory genes or acts through 
a more indirect mechanism. If we can identify specific MR target genes, this 
might help us understand the genes that are important in the macrophage 
phenotype during disease.  
 Another important aspect of MR function that has eluded the field for some 
time has been defining the physiological ligand of MR in tissues that lack  
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11β-HSD2. Corticosterone and aldosterone bind MR at nearly equal affinity, and 
corticosterone is present at 100 to 1000 times greater than aldosterone. Since 
macrophages do not express 11β-HSD2, which converts corticosterone to a low 
affinity form, it is presumed that MR is mostly occupied by glucocorticoids. This 
raises the question of how the MR activity is modulated in the macrophage. The 
answers to these questions regarding the mechanisms of functional control of 
macrophage activation and phenotype by MR will be essential to our 
understanding of its role in disease. Answering these questions about MR 
activation and function should no doubt yield interesting and valuable results, 
which will aid our understanding of the mechanisms of phenotypic control during 
disease.    
Conclusions 
 In this dissertation we have identified an important pathological role for 
myeloid MR during ischemic stroke, which advances our current understanding of 
the pathological mechanisms of MR and the mechanisms of pharmacological 
control by MR antagonists. It further highlights the importance of specific myeloid 
phenotypes during early infarct formation. A better understanding of the 
mechanisms by which myeloid phenotypes contribute to stroke damage could aid 
in the development of novel therapeutic agents to combat the harmful effects of 
inflammation during stroke.   
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